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ABSTRACT
 
 DNA G-quadruplexes (G4s) have gained interest in modern drug discovery efforts. 
The majority of G4 research, including the mass of this research, heavily focuses on 
cancer therapeutic development, as G4s are more pronounced in oncogenic promoters 
compared to the rest of the genome, our efforts extend towards neuroprotection as well. 
In particular, this work covers G4s in the promoters of MYC, VEGF, kRAS, and Bcl-2. 
MYC and VEGF harbor the two most well described promoter G4s to date, and their 
stabilization cultivates transcriptional silencing. Downregulation of MYC reduces cell 
growth and alters cell energetics; it is promising for a variety of cancer types, including 
lymphomas and leukemias. VEGF downregulation modulates angiogenesis, 
therapeutically benefiting most solid tumors. Lesser described G4s, kRAS and Bcl-2, act 
as transcriptional silencers and activators, respectively. kRAS is highly deregulated in 
30% of cancers, and its downregulation can decrease tumor cell proliferation and survival. 
Decreases in Bcl-2 expression result in pro-apoptotic signaling. However, Bcl-2 G41 
stabilization can cause transcriptional activation, and its upregulation reduces apoptosis, 
which is of therapeutic benefit for neurodegenerative diseases. The current study 
examines (a) the effect of epigenetic modification on VEGF G4 stability, (b) a variety of 
osmolytes and crowding co-solvents for their ability to recapitulate the physiological 
structure in single-stranded ex vivo conditions, (c) characterizing and targeting the 
biologically relevant G4 in the kRAS core promoter for a novel approach to targeting kRAS 
driven cancers, specifically pancreatic cancer, and (d) targeting one of four G4s (G41) 
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within the Bcl-2 promoter for neuroprotection. For all of the studies, significant changes 
in G4 structures, including loop directionality and number of competing isoforms, were 
examined by electronic circular dichroism. Electromobility shift assays differentiated inter- 
and intra-molecular structures, further distinguishing the distribution of isoforms. Other 
studies included chemical footprinting, FRET compound screening, luciferase, and in vitro 
cytotoxicity. This comprehensive understanding of the physiological conditions regulating 
G4 stability and function using co-solvents to examine the effects of small molecules ex 
vivo will best inform future drug discovery efforts on how to better predict active hits for in 
vitro evaluation for these and other promoters. 
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CHAPTER 1. INTRODUCTION
 Non-canonical DNA structures, such as G-quadruplexes (G4s), show promise as 
molecular targets for therapeutics, specifically in oncology. Unlike typical B-DNA, G4s 
form within a single strand leaving the complementary strand to remain continuous. G4-
forming regions are contained within very guanine dense sequences. This structure 
requires four guanines to hydrogen bond together, each acting as both proton donor and 
acceptor, to form a tetrad with the interconnecting nucleotides forming loops to connect 
guanines in the planes (Figure 1-1). This interaction between guanines is termed 
Hoogsteen base-pairing.  
 With an electronegative pocket at its center due to carbonyl oxygens, tetrads have 
increased stability when a monovalent cation is present (Williamson 1994; Guschlbauer 
et al. 1990). Many monovalent cations have been reported to stabilize tetrads, but the 
most commonly used are sodium and potassium. Early studies compared a manifold of 
cations ranging in ionic radii and found an inverse relationship between hydration energy 
and radii. Cations like K+, Rb+, Na+, Cs+, and Li+ were linked to complex G4 stability, but 
out of these alkalines, K+ produces the most stable intramolecular G4 (Bryan & Baumann 
2011). 
 G4s are polymorphic and can be categorized into four classes (Brooks & Hurley 
2010). The simplest forms are contained within Class I. This is when one form 
predominates in a single G-rich region with differences only being observed within loop 
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arrangements. A prime example of a Class I G4 is MYC. In G4-forming regions that allow 
more than one structure to form and are separated by an extended region of 
approximately three helical turns are contained within Class II. These G4s are typically 
dissimilar from each other, as seen with c-KIT and kRAS. Class III is similar to the second 
class as two G4s form, but they occur in closer proximity. The best example of this type 
is hTERT where two G4s form with only 4-19 intervening bases, and have interstructural 
interactions. The final class resembles the first in that structure formation occurs within a 
single G-rich region of DNA, but this class differs as more than one isoform exists within 
the same G4-forming region. For instance, the Bcl-2 promoter contains of a 39 bp G4-
forming region (G41) harboring six runs of guanines which allows at least three different 
G4s to form. 
 The first record of G4 formation was in 1910 when a Scandinavian chemist, Ivar 
Bang, discovered gel formation in aqueous solutions of high concentrations of guanosine 
derivatives (Bang 1910; Lagnado 2013). Interestingly, this phenomenon was described 
within fifty years of the identification of nuclein, or the nucleic acids (Miescher 1871; Wolf 
2003; Pray 2008), however, it was not until 1962 that this mystery was solved following a 
further understanding of nucleic acids (Chargaff 1950) and after the DNA double helix 
model was proposed (Watson & Crick 1953). Fiber x-ray diffraction data portrayed “G-
quartet” (tetrad) formation in telomeric DNA (Gellert et al. 1962). This sparked the G4 field 
of research, and the proposal that telomeric G4s could form and be therapeutic targets. 
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Figure 1-1. Guanine arrangement for G4 formation. In guanine rich sequences, four 
guanines Hoogsteen base pair to form a tetrad. Three or more tetrads stack on top of 
each other through π–π interactions, and the interconnecting nucleotides form the loops 
configured around the structure. The electronegative carbonyl oxygen pocket at the 
center of each tetrad allow for increased structural stability with a monovalent cation 
present. The structure described here is the initial promoter G4 elucidated within the MYC 
promoter (Adapted from Brooks & Hurley 2010). 
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 Telomeres exist on the ends of eukaryotic chromosomes and are very dynamic, 
as they contain a single-stranded 3’ overhang of approximately 200 nucleotides 
(Buscaglia et al. 2013). These DNA-protein structures can protect chromosome ends 
through a capping function in order to prevent DNA double-stranded breaks and from 
being processed by many other DNA damage pathways (Bidzinska et al. 2013). 
Telomeres shorten during cell division, and this shortening process is accelerated when 
telomere uncapping occurs. If telomeres become significantly short then the cell will no 
longer continue to proliferate and will instead enter senescence. However, there exists 
an enzyme, telomerase, that is expressed in fetal tissue, adult germ cell, and tumor cells 
and are responsible for chromosome lengthening and stabilization (Hanahan & Weinberg 
2000; Hanahan & Weinberg 2011). Its upregulation results in the replicative immortality 
phenotype seen in many cancers. Telomeres harbor tandem repeats of guanine rich 
sequences (Henderson et al. 1990). Thus, the discovery of G4s forming within these 
regions came to no surprise.  
 Telomeric G4s gained interest as therapeutic targets for cancer by acting on or 
controlling telomerase which is upregulated in approximately 85% of cancers (Kim et al. 
1994; Neidle & Parkinson 2003). Telomeric G4 caps block telomerase recruitment, 
resulting in cell senescence and apoptosis and acting to protect against extensive cellular 
division and mutation accumulation (Paeschke et al. 2008; Lipps & Rhodes 2009; Neidle 
2009; Neidle 2010). Collectively, the characterization of telomeric structures gave further 
insight into overall G4 formation, more specifically the differences in loop configurations. 
Based on the initial telomeric G4 findings using denaturing polyacrylamide gel 
electrophoresis and NMR studies, there were several isoforms existing with differences 
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in the loops and in structure, including both intra- and intermolecular types (Huppert 
2010). Briefly, intramolecular structures form within a single strand of DNA or RNA, and 
intermolecular G4s occur through the organization of two or more strands (Bryan & 
Baumann 2011). Intramolecular G4s are the structures of most interest as they are 
considered to be physiologically relevant with higher potential for small molecule targeting 
(Chen & Yang 2013). Also, they are polymorphic due to loop configurations. Loops can 
vary between G4s depending on the sequence which controls the final topology of the 
G4. Loops can link continuous guanines diagonally or laterally from the top or bottom of 
tetrads. A parallel conformation occurs when loops connect guanines located at the top 
to the bottom diagonally, using a double-chain reversal. Antiparallel structures contain 
loops connecting guanines in a diagonal or lateral fashion. There are G4s that exist in 
hybrid arrangements harboring both parallel and antiparallel loop directionalities known 
as mixed structures. The most stable G4s characterized have short loops in a parallel 
conformation as shown in Figure 1-1. 
 Outside DNA telomeric regions, G4s have been characterized in several gene 
promoters such as MYC, VEGF, c-KIT, hTERT, kRAS, and Bcl-2. These structures have 
the ability to activate or suppress transcription initiation depending on the gene it is native 
to and the regulatory proteins that bind the G4-forming region. G4s have been identified 
in RNA as well. Such structures form more readily than DNA G4s, as they do not need to 
compete with duplex formation. In 2010, telomeric repeat-containing RNA (TERRAs) 
were characterized to form RNA-G4s within living human cells (Xu et al. 2010). RNA-G4s 
have been described in vivo, and studies found that such structures are localized at the 
ends of chromosomes suggesting that RNA-G4s occur in telomeric regions of the human 
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genome. A few years later, a G4 structure-specific antibody, BG4, was engineered to 
investigate G4 existence in human cells and within individual chromosomes (Biffi et al. 
2013). G4s were visualized and suggested to form both within and outside the telomeric 
regions of chromosomes, which further validates the presence of promoter G4s. These 
breakthroughs indicate that G4s possess biological roles in replication and in regulating 
gene expression both transcriptionally and translationally. 
 Extensive evidence describes the folding of non-B-DNA arrangements in vitro 
throughout the genome. Following the completion of Human Genome Project in 2003, the 
understanding of G4s existing throughout the genome has increased exponentially. 
Computational analyses of putative G4 formation using the consensus sequence, (G3N1-
7)3G3, displayed a high density exists within promoters and 5’ untranslated regions (UTRs) 
(Verma et al. 2008). This was examined within the genomes of four species: human, 
chimpanzee, rat, and mouse, which suggests that the putative G4s described are 
evolutionarily conserved. In 2015, genome-wide sequence analysis was performed within 
the human genome from B lymphocytes (Chambers et al. 2015), and over 700,000 
distinct G4s were found, about 450,000 of them were not previously accounted from by 
computational methods using the putative G4 consensus sequence. The distinct G4s 
characterized were highly associated with oncogenes and tumor suppressor genes and 
were found in high densities regulatory regions. 
 It is estimated that approximately 40% of human gene promoters contain putative 
G4-forming regions (Huppert & Balasubramanian 2006). Localization has been reported 
to be significantly higher in proto-oncogenes than in housekeeping or tumor suppressor 
genes (Eddy 2006). Gene promoters tend to be rich in guanines where chromatin 
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structure is open, allowing for easier transcriptional activation. G4 formation is permitted 
in promoter regions when DNA transcriptional machinery (RNA Pol II and transcription 
factors) bind to double-stranded DNA (dsDNA). Strand separation occurs due to the 
negative supercoiling that occurs behind the transcriptional machinery, upstream from the 
transcriptional start site (TSS) (Wang & Dröge 1996; Kramer & Sinden 1997; Champoux 
2001; Brooks & Hurley 2009). Torsional stress is usually relieved by topoisomerases. 
However, competition arises with other regulatory binding proteins which may preclude 
access for topoisomerase binding (Champoux 2001). Also, this form of regulation has 
been reported as insufficient in removing all supercoiling that is generated during 
transcription which would allow secondary structure formation (Wang & Dröge 1996). 
 As mentioned, there exists a plethora of G4s within oncogenes and tumor 
suppressor genes that have previously been characterized such as MYC, kRAS, hRAS, 
nRAS, c-KIT, Bcl-2, pRB, VEGF, HIF-1, hTERT, and more. In fact, there is at least one 
example of a G4 forming and acting upon critical genes responsible for each of the ten 
hallmarks of cancer (Figure 1-2) (Brooks & Hurley 2010; Cogoi & Xodo 2006; Morgan & 
Brooks 2016; Morgan et al. 2016; Onyshchenko et al. 2009; Sun et al. 2014; Phan et al. 
2004; Huang et al. 2012; Bonnal et al. 2003; Ambrus et al. 2006; Agarwala et al. 2013; 
Williamson 1994). Most promoter G4s have been found to act as transcriptional silencers 
through the disruption of regulatory protein binding. The most characterized G4 to date is 
within the MYC promoter, which is responsible for downregulating transcription via 
obstructing Sp1, CNBP, and hnRNP-k protein binding (Brooks & Hurley 2009). In 
contrast, there exists a G4 that forms within the Bcl-2 promoter that displaces 
transcriptional suppressor, WT1, binding resulting in activation instead (Brooks et al. 
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2010). Therefore, structure stabilization for transcriptional control has become a key 
interest for G4 research and drug discovery programs utilizing a small molecule approach. 
 G4 research heavily concentrates on cancer drug discovery. With MYC being the 
first promoter G4 characterized and the most extensively studied structure to date, there 
have been numerous attempts to target the structure with a large variety of small 
molecules. These studies led to the design of a first-in-class G4-interacting drug, 
Quarfloxin (Drygin et al. 2009). This compound bound MYC G4 with higher affinity than 
universal G4-binding agents and led to decreased mRNA expression isolated from a 
mouse xenograft model of human colorectal cancer cells. Unfortunately, due to high 
plasma protein binding, Quarfloxin did not proceed past Phase II trials. To date, 
Quarfloxin and compound CX-5461 are the only G4-stabilizing agents to make it to clinical 
trials with CX-5461 being the most recent and is currently being tested (Xu et al. 2017). 
However, prospective drug discovery designs utilizing G4s to control gene expression 
through transcription have potential. The current pitfalls are due to the gap in knowledge 
of bridging physiological G4 formation with that in small molecule screening which takes 
place outside of cells. We aim to gain such knowledge through the following aims: 
Specific Aim 1. Discern biologically relevant G4s by examining the role of epigenetic 
modifications on G4 stability and recognition, utilizing physiological conditions of a 
cell’s nucleus extracellularly, and distinguish G4 biological activity on transcription. 
Specific Aim 2. Screen for small G4-stabilizing agents for anti-cancer or 
neuroprotective agents using physiological conditions extracellularly.  
9 
 
 
 
Figure 1-2. G4s in the hallmarks of cancer.  
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CHAPTER 2. MATERIALS & METHODS
2.1. Reagents 
Most oligonucleotides were synthesized and purchased from Eurofins MWG Operon, LLC 
(Louisville, KY) with the exception of 5-hmC oligonucleotides which were purchased from 
Midland Certified Reagent Co., Inc. (Midland, TX) (Table 2-1). Acrylamide/bisacrylamide 
(29:1) solution and ammonium persulfate were purchased from Bio-Rad laboratories 
(Hercules, CA), and N,N,N’,N’-tetramethylethylenediamine was purchased through 
Thermo Fisher Scientific (Pittsburgh, PA). Unless specified, all other chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO). 
 2.2. DNA Solvation & Concentration Determination 
Upon receiving, DNA was resuspended in water and thoroughly vortexed for 2 min before 
being heated at 95 °C for 10 min. Concentrations were determined, while the DNA was 
still hot, using the ratio of the observed A260 via a NanoDrop2000 to the E260 of the 
oligonucleotide (as reported by IDT Oligo Analyzer). 
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Table 2-1. List of all oligonucleotide sequences. 
VEGFKO 5’CCGTTGCGTGCCGTTTGCGTTGTC3’ 
VEGF1-4 5’CCGGGGCGGGCCGGGGGCGGGGTC3’ 
VEGFmod1 5’CCGGGG(5-HM-dC)GGGCCGGGGGCGGGGTC3’ 
VEGFmod2 5’CCGGGGCGGG(5-HM-dC)CGGGGGCGGGGTC3’ 
VEGFmod3 5’CCGGGGCGGGCCGGGGG(5-HM-dC)GGGGTC3’ 
MYCKO 5’GCGCTTATGTTGAGTGTGTTGAGTGTGTTGAAGGTGTTGAGGAGAC3’ 
MYCKO EMSA 5’[6~FAM]GCGCTTATGTTGAGTGTGTTGAGTGTGTTGAAGGTGTTGAGGAG
AC3’ 
MYC 5’GCGCTTATGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGAGGAGAC3’ 
MYC EMSA 5’[6~FAM]GCGCTTATGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGAG
GAGAC3’ 
MYC FRET 5’[6~FAM]GCGCTTATGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGAG
GAGAC[TAMRA~6~FAM]3’ 
G4near-KO 5’AGGGCTTTTTGGGAAGAGTGAAGAGGGGGAGG3’ 
G4near-KO EMSA 5’[6~FAM]AGGGCTTTTTGGGAAGAGTGAAGAGGGGGAGG3’ 
G4near 5’AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG3’ 
G4near EMSA 5’[6~FAM]AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG3 
G4mid-KO 5’CGGGGAGAAGGAGTTTGCCGGGCCGGGCCGGCGGGGGAGGAGCGTTT
GCCGGGC3’ 
G4mid-KO EMSA 5’[6~FAM]CGGGGAGAAGGAGTTTGCCGGGCCGGGCCGGCGGGGGAGGA
GCGTTTGCCGGGC3’ 
G4mid 5’CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGGAGGAGCGG
GGGCCGGGC3’ 
G4mid EMSA 5’[6~FAM]CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGGAGG
AGCGGGGGCCGGGC3’ 
G4mid DMS 5’[6~FAM]TTTTTTTCGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGG
GGAGGAGCGGGGGCCGGGCTTTTTTT3’ 
G4mid FRET 5’[6~FAM]GCGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGGAG
GAGCGGGGGCCGGGC[TAMRA~6~FAM]3’ 
G4mid DMS Forward 
Primer 
5’-[6~FAM]GATGCGTTCCGCGCTCGA-3’ 
G4mid DMS Reverse 
Primer 
5’-[6~FAM]AGTCCCTCCTCCCGCCAA-3’ 
Mut A 5’CGTTGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGGAGGAGCGGG
GGCCGGGC3’ 
Mut B 5’CGGGGAGAAGGAGGTGGCCGGGCCGGGCCGGCGGGGGAGGAGCGGG
GGCCGGGC3’ 
Mut C 5’CGGGGAGAAGGAGGGGGCCGTGCCGGGCCGGCGGGGGAGGAGCGGG
GGCCGGGC3’ 
Mut D 5’CGGGGAGAAGGAGGGGGCCGGGCCGTGCCGGCGGGGGAGGAGCGGG
GGCCGGGC3’ 
Mut E 5’CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGTGGAGGAGCGGG
GGCCGGGC3’ 
Mut F 5’CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGGAGGAGCGGT
GGCCGGGC3’ 
Mut G 5’CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGGAGGAGCGG
GGGCCGTGC3’ 
G4far-KO 5’AAGGTGTGGCTGTTGCGGTCTAGTGTGGCGAGCCGTGCC3’ 
G4far-KO EMSA 5’[6~FAM]AAGGTGTGGCTGTTGCGGTCTAGTGTGGCGAGCCGTGCC3’ 
G4far 5’AGGGGTGGCTGGGGCGGTCTAGGGTGGCGAGCCGGGC3’ 
G4far EMSA 5’[6~FAM]AGGGGTGGCTGGGGCGGTCTAGGGTGGCGAGCCGGGC3’ 
G40 5’CGGGCGGGAGCGCGGCGGGCGGGCGGGC3’ 
G41 5’AGGGGCGGGCGCGGGAGGAAGGGGGCGGGAGCGGGGC3’ 
G41 FRET 5’[6~FAM]AGGGGCGGGCGCGGGAGGAAGGGGGCGGGAGCGGGGC[TAM
RA~6~FAM] 
G42 5’CGGGCCAGGGAGCGGGGCGGAGGGGGCGGTCGGGT3’ 
G43 5’GCTGGGGTCCGCGACGGGGTGGGGGCTCCCGGGGAAC3’ 
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2.3. Electronic Circular Dichroism (ECD) 
The G4 oligonucleotides (5 µM) were diluted in 50 mM Tris-HCl (pH 7.4) with varying 
amounts of KCl and co-solvents (0 - 40%). The co-solvents utilized were (1) osmolytes: 
acetonitrile (MeCN), glucose, sucrose, dextran sulfate, and ficoll and (2) molecular 
crowding agents: polyethylene glycol 300 (PEG), glycerol, and extracted nucleoplasm. 
Samples were heated at 95 °C and snap cooled on ice for 5 min each and repeated up 
to five times depending on the DNA. Concentration was determined using the ratio of 
A260 observed with a NanoDrop2000 by the E260 of the oligonucleotide. Spectra were 
collected with an Olis DSM-20 spectropolarimeter equipped with a ECD 250 Peltier cell 
holder (Bogart, GA). Recordings were made over the wavelength range 225-350 nm 
(every nm) and at increasing temperatures (20-100 °C, every 10 °C, with a 1 min. hold at 
temperature before spectra were recorded) in 1 mm quartz cuvette. The ordinate is 
reported as molar ellipticity (converted from millidegrees based on sample concentration); 
TM’s were determined by performing a singular value decomposition (SVD) analysis 
available with the Olis GlobalWorks software, followed by non-linear regression fitting 
sigmoidal inhibition dose-response on GraphPad Prism software (La Jolla, CA) in order 
to determine the 50% melting point (TM). 
2.4. Electrophoretic Mobility Shift Assay (EMSA) 
FAM-labeled oligonucleotides, MYC and kRASmid, were prepared in 10 mM KCl or 100 
mM KCl, 50 mM Tris-HCl (pH 7.4), and one of the following: 2-100% extracted 
nucleoplasm, 20% sucrose, 20% MeCN, 10% dextran sulfate, 20% PEG, or 10 µM G4-
stabilizing compounds. The solutions were each denatured by heating to 95 °C for 5 min, 
and rapidly cooled on ice for 5 min, and repeated for one to five cycles, depending on the 
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G4, to induce structure formation. Upon addition of non-denaturing loading dye (1:1 ratio 
of 6x loading dye and 50% glycerol), the samples were loaded onto a 10-16% native 
polyacrylamide gel (10-16% of acrylamide-bisacrylamide solution, 1x TBE buffer, 10 mM 
KCl, 1% APS, 0.1% TEMED). After running at 100 V, the gel was visualized under blue 
light LED using a FOTO/Analyst® Investigator FX Imager (Hartland, WI). 
2.5. Cell Culture 
Burkitt’s lymphoma cells, RAJI and CA46, were maintained in Roswell Park Memorial 
Institute (RPMI) 1640 medium. Pancreatic cancer, Panc-1, MiaPaCa-2, and AsPc-1, and 
human embryonic kidney, HEK-293 cells were preserved in Dulbecco’s modified eagle’s 
medium (DMEM). Neuroblastoma cells, SH-SY5Y, were kept in Dulbecco’s modified 
eagle/nutrient mixture F-12 medium (DMEM/F-12). All media types were supplemented 
with 10% fetal bovine serum and 1x penicillin/streptomycin solution, and cells were 
incubated at 37 °C, in a humidified environment containing 5% CO2. Each cell line was 
obtained from ATCC (Manassas, VA).  
2.6. Cellular Nucleoplasm Extraction 
MiaPaCa-2 cells were grown to ~90% confluency in 75 mL flasks, trypsinized, and 
collected in a 50 mL conical tube. Cells were resuspended and centrifuged at 4,000 rpm 
for 5 min. in ~5 packed cell volume (pcv) hypotonic buffer solution (10 mM HEPES, pH 
7.9, 1.5 mM MgCl2, 10 mM KCl) after adding 0.2 mM phenylmethylsulfonyl fluoride 
(PMSF) and 0.5 M dithiothreitol (DTT). The pellet was then resuspended in 3 pcv 
hypotonic buffer solution, and the cells were allowed to swell on ice for 10 min. Cells were 
homogenized and spun at 4,000 rpm for 15 min. and were then resuspended in ½ packed 
nuclear volume (pnv) low-salt buffer solution (20 mM HEPES, pH 7.9, 25% glycerol, 1.5 
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mM MgCl2, and 0.2 mM EDTA) after adding 0.2 mM PMSF and 0.5 M DTT. Slowly, ½ 
pnv high-salt buffer solution (add 0.8 M KCl to low-salt buffer stock) was added in a drop-
wise fashion upon addition of 0.2 mM PMSF and 0.5 M DTT. Cytoplasmic extract was 
incubated at room temperature for 30 min with continuous mixing and then centrifuged at 
14,000 rpm for 30 min; supernatant was collected as the nuclear extract. 
2.7. Dimethyl Sulfate (DMS) Footprinting 
FAM-labeled oligonucleotides (2 μM) were prepared in 50 mM Tris-HCl (pH 7.4), 10 or 
100 mM KCl, alone or with one of the following: 2-5% extracted nucleoplasm, 20% 
sucrose, 20% MeCN, 10% dextran sulfate, 20% PEG or 10 µM G4-stabilizing compounds. 
Samples were denatured at 95 °C for 5 min and then cooled at 4 °C for 5 min. This was 
repeated for one to five cycles, depending on the G4, to allow structure induction. 
Oligonucleotide solutions were then treated with 1% DMS (one part DMS to 4 parts 
ethanol) and incubated at room temperature for 15 min. The reaction was stopped with 
5% β-mercaptoethanol. The samples were separated on a 10% native gel at 100 V. 
Bands were visualized on a FotoDyne Imager, excised with scalpel, and DNA was eluted 
from the gel overnight. Upon filtration by centrifugation, the DNA underwent ethanol 
precipitation (70% EtOH, 0.3M NaOAc) overnight at -20 °C. Solutions were centrifuged 
at 14,000 rpm for 30 min and resuspended in 10% piperidine. This treatment was 
incubated at 90 °C for 30 min and ethanol precipitation overnight as previously described. 
Samples were spun at 14,000 rpm for 30 min, dried, and then resuspended in 50 μL DMS 
dye (95% formamide, 0.01% bromophenol blue, 20 mM EDTA). Finally, solutions were 
heated at 95 °C for 5 min and placed on ice until being loaded onto a 16% denaturing 
15 
 
polyacrylamide gel run at 500 V. The gel was then visualized on a FOTO/Analyst® 
Investigator FX Imager (Fotodyne, Inc., Hartland, WI). 
2.8. Fluorescence Resonance Energy Transfer (FRET) Melt 
A dual-labeled DNA oligomer probe (200 nM) bearing the G4-forming regions of the MYC, 
kRASmid, or Bcl-2 promoters were used to screen compounds of interest (10 μM). DNA 
was diluted in 10 mM Tris-HCl + 90 mM LiCl, 10 mM sodium cacodylate, heated at 95 °C 
and rapidly cooled on ice. Annealed G4 DNA was added to a 96-well PCR plate with or 
without test compounds and incubated at room temperature for 30 min. Fluorescence 
was recorded from 25-95 °C, at every degree after a 30 sec hold on a Bio-Rad CFX 
Connect real-time PCR machine (Hercules, CA). Over 1,600 compounds were screened 
from NCI Diversity Set III for stabilizing kRAS G4mid, and all other compounds screened 
were from an “in-house” 96-well plate containing known pan-G4-stabilizing agents, as 
well as, compounds isolated or synthesized at the University of Mississippi. 
2.9. MTS Cell Viability 
All cells were plated in 96-well plates in 90 μL of media. Burkitt’s lymphoma cells, RAJI 
and CA46, were plated at 75,000 cells/well, pancreatic cancer cells, Panc-1, MiaPaCa-2, 
and AsPc-1, were plated at 10,000 cells/well and were allowed to attach for 24 hr, 
neuroblastoma cells, SH-SY5Y, were plated at 60,000 cells/well and allowed to attach for 
48 hr. Following the attachment time, compounds (10 μL of 10x) of interest were added 
over a 5-6 log range and incubated at 37 °C with 5% CO2 for 24-72 hr depending on the 
range listed above. Changes in cellular viability were determined by the MTS assay: 2 mL 
of sterile filtered 2 mg/mL MTS in PBS with 5% PMS added immediately before use, 
plates were then incubated at 37 °C with 5% CO2 for 2-4 hr before recording absorbance 
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using a BioTek Synergy 2 spectrophotometer (BioTek Instruments, Inc., Winooski, VT). 
The recorded absorbance of the formazan dye at 490 nm were normalized to control cells; 
GraphPad Prism non-linear regression fitting sigmoidal inhibition dose-response was 
used to calculate the IC50. 
2.10. Quantitative Real-Time PCR (qRT-PCR) 
Pancreatic cancer cells (BxPc3, Panc-1, MiaPaCa-2, AsPc-1) were plated at 100,000 
cells/well in a 12-well plate and incubated overnight at 37 °C 5% CO2. DMSO or 
compounds of interest were added to the seeding media final concentrations 
approximating the IC50 (as determined by MTS cell viability assay). After 24 hr, samples 
were resuspended in lysis buffer (guanidine thiocyanate mixed with EtOH, and 20 μL 14.3 
M β-mercaptoethanol added to each 1000 μL buffer used), and RNA was extracted using 
Thermo Scientific GeneJET RNA purification kit. RNA concentrations were determined 
using a NanoDrop 2000 (Thermo Scientific), and only samples with 260/230 values >2 
were used to synthesize cDNA. 200ng of cDNA was synthesized using iScriptTM cDNA 
synthesis kit (Bio-Rad), and qRT-PCR was run on an Applied Biosystems 7500 real-time 
PCR detection system (ThermoFisher Scientific) using TaqMan primers from ABI (kRAS: 
Hs00364284_g1, MYC Exon 2: Hs00153408_m1, MYC Exon 1: Hs01562521_m1, Bcl-2: 
Hs00608023, GAPDH: Hs02758991_g1). mRNA expression was normalized to GAPDH, 
and again to vehicle controls using the Cq method. Experiments were run in biological 
duplicates and technical triplicates; statistical significance was determined by one-way 
ANOVA with post-hoc Tukey analysis. 
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2.11. Plasmid DMS Footprinting 
DMS footprinting was performed in a cell-free environment with the supercoiled kRAS 
plasmid having the promoter region from +50 to -324 described above. The plasmid (500 
ng) was combined with 100 mM KCl alone or with 100 μM TMPyP4 and incubated at 37 
°C overnight, after which, DMS and piperidine treatment will be performed as described 
above. 1.25 units HotStart polymerase, 1x standard Taq reaction buffer, 200 μM dNTPs, 
and 200 nM FAM-labeled primers (Forward: 5’-GATGCGTTCCGCGCTCGA-3’, Reverse: 
5’-AGTCCCTCCTCCCGCCAA-3’) will be added for PCR amplification (Initial 
denaturation: 95 °C for 30 sec; 30 cycles: 95 °C 20 sec, 58 °C 30 sec, 68 °C 1 min; Final 
extension: 68 °C 5 min). The products were separated on a denaturing PAGE gel and 
visualized on a FOTO/Analyst® Investigator FX Imager (Fotodyne, Inc., Hartland, WI). 
2.12. Plasmid Construction 
Using the pGL4.17 plasmid (Promega) as a backbone, several luciferase plasmids were 
constructed. Promoter-driven, SV40, MYC Del4, and Bcl-2 plasmids were purchased 
through Addgene (Cambridge, MA). The kRAS promoter regions of interest were inserted 
between the Nhe I and HIND III cut sites. G4near, G4FL, and G4mid were constructed by 
Operon while we synthesized the “no G4”, mut near and mut G4mid constructs. Using the 
primers, 5’-GACGCTAGCTCAGCCGCTCCCTCTCGTAC-3’ and 5’-
GACAAGCTTACCTTCGCCGCCGCCACTGC-3’, the “no G4” plasmid was constructed 
by PCR from the G4near plasmid. The PCR product was ran on a 1.5% agarose gel, 
extracted, and cut by Nhe I and HIND III enzymes overnight. Then, the product was 
ligated into an EV plasmid. The mut G4near and mut G4mid plasmids were constructed 
using G4FL and the Q5® Site-Directed Mutagenesis kit (New England BioLabs, Inc.). Mut 
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G4near required primers 5’-TTTGGGAAGAGGGAAGAGGGG-3’ and 5’-
AAGCCCTCAGCCGCTCCCTCTC-3’, and the mut G4mid used primers 5’-
GCGGGGGAGGAGCCCGGCGGAGGAAG-3’ and 5’-
CGGCCCGGCCCGGCTCCCCGCCGGCG-3’. Product size was validated using an 
agarose gel. 
2.13. Transfection and Luciferase Assays 
HEK-293 cells were plated 200,000 cells/well in 6-well plates and allowed to attach 
overnight. SH-SY5Y cells were plated 100,000 cells/well in 24-well plates and allowed to 
attach for 48 hr. Each well was then co-transfected with the plasmid of interest (200 ng 
kRAS plasmids, 450 ng Del4 and Bcl-2) and the reference plasmid pRL-SV40, in equal 
amounts to plasmid of interest, formed into micelles with FuGene HD (Promega) in a 3:1 
ratio with cells in OptiMEM medium (Invitrogen; Grand Island, NY). An unmodified 
pGL4.17 plasmid (Empty Vector, EV) was used as a negative control vector, at equal 
amounts to plasmid of interest. A promoter-driven plasmid, SV40, was used as a positive 
control at equal amounts to plasmid of interest. Transfections were maintained at 37 °C 
in 5% CO2 overnight before media was replaced with DMEM alone or with test compound. 
After 24 or 48 hrs of incubation, the expression of firefly, with respect to Renilla, luciferase 
was established using the Dual-Reporter Luciferase assay kit (Promega); luminescence 
was measured with a Lumat LB9507 luminometer (Berthold Technologies). All 
experiments were performed in biological duplicate with technical duplicates. Statistical 
significance was determined by a one-way ANOVA with post-hoc Tukey analysis or a 
two-way ANOVA with Bonferroni post-test analysis (in SH-SY5Y samples). 
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2.14. Neuroprotection Studies 
Neuroblastoma cells were plated at 90,000 cells/well in 96-well plates and allowed to 
attach for 48 hr. For serum starvation, our environmental stressor, media was removed 
and replaced with new media containing 1% or 10% of fetal bovine serum (FBS); 
inflammatory stress was emulated upon 250 µM H2O2 incubation 3 hr prior to MTS 
addition. Neurotoxicity was induced with 100 µM 6-hydroxydopamine (6-OHDA). 
Compounds of interest were added to each condition listed in the same way as in the 
MTS cell viability assay described above. Neuroprotection was measured by observing 
the changes in cell viability. All experiments were performed in biological duplicate with 
internal technical triplicates. 
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CHAPTER 3. PHYSIOLOGICAL MIMICRY
3.1. Introduction 
G4s are common throughout the genome with high abundances in promoters and 
5’UTRs in oncogenes and tumor suppressor genes (Verma et al. 2008; Chambers et al. 
2015). G4s are highly polymorphic, both across regions of DNA and within one sequence, 
and vary in the number of stacked tetrads, as well as in loop directionality. It is suggested 
that short loop lengths are favorable, but there are G4s having been characterized 
harboring long loops like kRAS, hTERT, and Bcl-2. These non-canonical DNA structures 
have been characterized as transcriptional regulators, as either activators or suppressors 
depending on the gene involved. Most G4s identified are transcriptional suppressors by 
hindering RNA polymerase activity and/or transcription factor binding. Such structures 
span the hallmarks of cancer, thus, most research focuses on utilizing small G4-stabilizing 
molecules in order to decrease tumor activity. 
During replication or transcription, the complimentary strands of gene promoter 
regions are separated. Separation of the dsDNA helix to single stranded DNA (ssDNA) 
has the potential to form G4 structures (Ahmed et al. 1994; Michelotti, Gregory A. 1996; 
Rangan et al. 2001; Simonsson et al. 2000). At physiological pH, G4s have previously 
been described to form complexes with crowding reagents aiding in the stability of 
structure formation. Also, these studies have confirmed that G4s are highly polymorphic 
and differ between genes. The average topology of G4s vary depending on the 
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environment as well as the sequences, specifically pH, dehydrating conditions, and 
epigenetics (Miller et al. 2010; Zhang et al. 2010; Dailey et al. 2010). 
As the interest in G4 function in biological systems grows, understanding the 
structure thermodynamics in the presence of biomolecules will help to clarify what occurs 
in physiological conditions. Biomolecules possess functions within living cells and inhabit 
a marked portion of a cell’s volume (approximately 20-40%) (Miyoshi et al. 2006). It has 
been reported that molecular crowding affects the stability of DNA as a result of changes 
in hydration (Goobes et al. 2003; Spink & Chaires 1999). In particular, PEG has been 
found to induce alterations in G4 structure with K+ present. This was due to fewer 
hydroxyl groups within the co-solvent as these groups affect DNA hydration. Molecular 
crowding with a K+ cation present causes dehydration and stabilization of G4s while it 
destabilizes duplex DNA as Watson-Crick base pairs consist of more hydration sites than 
Hoogsteen-base pairs (Misra & Draper 1998). This suggests that non-canonical DNA 
structures can be favored over B-DNA duplexes depending on the sequence and 
surrounding nuclear conditions which directs structural polymorphisms found to be 
regulated via hydration states. However, previous studies have not explored the effect 
epigenetic DNA modifications has on G4 structures in the presence of the most relevant 
co-solutes to recapitulate intranuclear higher order formations. 
Relevant in the study of genetics, epigenetics is the study of cellular traits that are 
influenced by external or environmental factors. The genes producing the cellular traits 
can be upregulated or downregulated based on the effects the influential factors have on 
transcription (Simmons 2008). Not to be confused with traditional studies in genetics, 
which focuses on base sequence changes, the central focus of epigenetics is on 
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modifications to a DNA sequence not involving base sequence changes (Carey 2011). 
Modifications such as methylation or hydroxymethylation to bases in a DNA sequence 
have been discovered as epigenetic external factors regulating gene expression. 
Enzymes of the methyltransferase and ten-eleven-translocation (TET) family of 
oxygenases typically generate the methylated or hydroxymethylated bases, respectively 
(Bhavsar-Jog, Van Dornshuld, Brooks, et al. 2014). Unique regions in a genome prone to 
these types of modifications are CpG islands. CpG islands consist of repeats of a cytosine 
being placed next to a guanine in the same sequence with only a phosphate separating 
the two nucleotides (Josse et al. 961; Morrison, J. M. 1967). The occurrence of CpG 
islands in mammals is quite low, less than 1% in humans (Scarano, E. 1967). Low 
occurrence of CpG islands can be linked to the likelihood of cytosines being methylated 
causing deamination to thymine. However, when CpG islands occur, the chance of 
external modification on a cytosine increases the probability of altering gene expression 
(Jabbari & Bernardi 2004). Hypermethylation can suppress gene transcription important 
for cellular growth and function such as tumor suppressor genes while hypomethylation 
can upregulate oncogenes promoting tumorigenesis. These actions can be especially 
important in cancer-causing genes containing G4-forming regions as these regions exist 
within CpG islands and are highly susceptible to epigenetic modifications, specifically 5-
hydroxymethylated cytosines (5-hmC) (Halder et al. 2010).  
Non-canonical DNA structures have been discovered to exist within many 
oncogene and tumor suppressor gene promoters. Previous ones that have been 
characterized include MYC, Bcl-2, hRAS, pRb, c-KIT, PDGF-A, and VEGF genes. Of 
these known G4s, MYC and VEGF have been extensively studied. The G4-forming region 
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within the VEGF promoter occurs within a CpG island. This is not true for the MYC 
promoter, thus VEGF is an ideal candidate for investigating the role of epigenetic 
modifications on G4 stability in the presence of co-solutes. On the other hand, MYC is an 
ideal candidate for exploring the incorporation of co-solvents into G4 drug discovery 
screens in order to simulate intranuclear conditions in vitro. 
Several compound classes have been identified to bind and stabilize G4s. Many 
molecules universally bind G4 structures and impact gene expression in vitro with little 
influence in cells or in vivo. It is challenging to classify new chemical scaffolds as selective 
G4 stabilizing agents; the techniques utilized in order to ascertain small molecule-
mediated stabilization of G4s are insufficient and not optimal as they are performed under 
simple conditions. Standard initial protocols for screening G4-stabilizing compounds, 
such as FRET melt and ECD, are operated in buffer in vitro with ssDNA and the addition 
of a salt (KCl or NaCl). This allows for structure formation, but it does not fully coincide 
with physiologically relevant conditions or the biologically active G4 isoforms. Thus, drug 
discovery and development programs are hindered, as there have been a lack of lead 
compounds that selectively modulate G4-driven genes. To date, one agent triumphed to 
clinical trials for stabilizing the G4 associated with transcription factor MYC which plays a 
role in tumorigenesis and disease progression (Brooks & Hurley 2010). However, 
Quarfloxin (CX-3543) did not succeed phase II trials due to high albumin binding 
(Balasubramanian & Hurley 2011). Consequently, modern G4 drug discovery efforts 
require attention and optimization to ensure in vitro success that will correlate to increased 
favorability in vivo. 
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Applying G4 stabilization to gain transcriptional control of gene regulation in order 
to suppress oncogene expression is a promising cancer therapeutic approach. 
Stabilization of these structures within promoter regions act as blockades to RNA 
polymerase and other gene regulatory proteins. Enhancing the formation and stability is 
therefore potentially therapeutic, and as these structures are more “globular” than 
traditional dsDNA, future drug discovery programs can focus on particular 
genes/structures with increased selectivity as compared to dsDNA. Extracellularly, 
stabilization can occur by the addition of alkali cations, modifying water content, or by 
integrating molecular crowding. Intracellularly, stabilization can be attained 
pharmacologically by applying small molecules. Ligand-mediated G4 stabilization has 
been a growing drug discovery program since their initial characterization. Gaining more 
knowledge on how these structures form will aid in the development of future drug 
discovery efforts. Also, pharmacological modulation of G4-driven genes with small 
molecules will have higher success (decreased false positives and false negatives) when 
transitioning from in vitro to in vivo upon utilization of co-solvents to simulate nuclear 
conditions of a cell. Dehydrating and molecular crowding agents, specifically MeCN and 
PEG, have been studied previously and were found to increase G4 thermodynamic 
stability. Modifying water content has also been shown to enhance binding affinity of 
ligands to DNA (Winn et al. 2009). Hence, the addition of co-solvents to G4 screening 
protocols would enable anhydrous molecular crowding and simple dehydration, 
mimicking intracellular conditions, and result in a minimization of false positives for ligand 
binding. 
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We hypothesize that 5-hmC-containing G4s may alter G4 stability and recognition 
by G4-stabilizing small molecules and regulatory binding proteins. We determined this by 
examining the role of cationic strength, pH, and water content on structures containing 5-
hmC modifications in G4 loops. We sought to define whether 5-hmC modifications could 
influence the average topology and stability of VEGF G4 structures which contains natural 
CpG islands. Also, we investigated the enhancement of current G4 drug discovery 
programs through the use of co-solvents to mimic physiological conditions of a cell’s 
nucleus. Here, we hypothesize that the use of co-solvents to recapitulate physiological 
conditions extracellularly will increase success in G4 drug discovery programs when 
testing compounds outside of cells, confirming the mechanism inside of cells, as well as 
in examining in vivo efficacy. Collectively, these works can be divided into the following 
aims: 
Specific Aim 1. Quantify the thermodynamic properties and underlying equilibrating G4 
structures containing 5-hmC modifications. 
Specific Aim 2. Determine the role of co-solvents on G4 folding, stability, and 
polymorphic nature and apply this physiological mimicry to G4 drug discovery 
programs.  
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3.2. 5-hydroxymethylcytosine Modification Effects on G4 Formation and Stability 
 Vascular endothelial growth factor (VEGF) produces a protein that stimulates 
angiogenesis allowing oxygen restoration to tissue (Senger, 1983). When overexpressed, 
VEGF is responsible for the rapid development of new blood vessels to cells, specifically 
tumor cells. This can cause vascular disease and can help tumors metastasize. VEGF is 
a key player in tumorigenesis for many cancer cell types making it a promising target for 
drug therapy. The promoter within this oncogene contains a main cis-element located -
85 to -50 bp from the TSS. This element is a G4 forming region consisting of five 
contiguous runs of guanines. Previous studies have described the G4 structures that form 
with the first four runs in ssDNA. Besides enabling G4 formation, this G/C rich region 
close to the TSS contains a CpG island favorable for cytosine methylation or 
hydroxymethylation. Thus, we utilized VEGF oligonucleotides containing 5-hmC 
modifications, compared to wild-type (VEGF1-4), on three different cytosines with the 
potential for natural cytosine modification, each involved in loop formation within the G4 
(Table 3-1) (Figure 3-1A). The ssDNA oligonucleotides containing modifications were 
predicted based on CpG mono- or di-nucleotide motifs. It is important to note that the 
cytosine modified for VEGFmod2 was chosen as cytosine modifications occur on the most 
distal nucleotide in a CCG(1-2) motif (Stroud et al. 2011). 
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Table 3-1. VEGF modification oligonucleotide sequences. 
VEGFKO 5’CCGTTGCGTGCCGTTTGCGTTGTC3’ 
VEGF1-4 5’CCGGGGCGGGCCGGGGGCGGGGTC3’ 
VEGFmod1 5’CCGGGG(5-HM-dC)GGGCCGGGGGCGGGGTC3’ 
VEGFmod2 5’CCGGGGCGGG(5-HM-dC)CGGGGGCGGGGTC3’ 
VEGFmod3 5’CCGGGGCGGGCCGGGGG(5-HM-dC)GGGGTC3’ 
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Figure 3-1. 5-hmC modifications within VEGF G4 allow stable G4 formation. Wild-type 
VEGF forms a parallel G4 with cytosines contained within the loops that may possess 5-
hmC modifications. These potential sites have each been modified in different 
oligonucleotides named mod 1, 2, and 3 depending on the location of the 5-hmC (A) ECD 
spectra shows stable G4 formation with each of the modifications in 10 mM KCl, similar 
to wild-type (B) 
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 Overall G4 formation and stability of 5-hmC modifications was examined by ECD 
as compared to the wild-type, each in the presence of 10 mM KCl alone. VEGF1-4 forms 
a prominent parallel structure as examined by the positive Cotton effect at 265 nm (Figure 
3-1B) (Agrawal et al. 2013; Guo et al. 2008; Sun et al. 2005; Sun et al. 2008). 
Thermodynamic stability is conserved with each modification present individually 
compared to wild-type (1-4: 67 °C, Mod1: 68 °C, Mod2: 68 °C, Mod3: 67 °C). Further 
studies were performed to challenge G4 formation when epigenetic modifications are 
present such as using select co-solvents to mimic physiological conditions outside of 
cells. Appropriate co-solvent concentrations were determined by depicting the minimal 
concentration necessary (0-40%) to induce maximal G4 formation through analyzing ECD 
spectra of VEGF1-4 (Figure 3-2). The concentrations of, 10 mM KCl, and 30% MeCN or 
10% PEG, were chosen to investigate modified G4 formation. We observed the effect of 
these co-solvents on G4 stability with epigenetic modifications present compared to wild-
type (Figure 3-3A). VEGF1-4 thermal stability increased from 67 °C to 83 and 77 °C upon 
addition of MeCN and PEG, respectively. A knockout oligonucleotide, VEGFKO, with G>T 
mutations in each guanine run within the wild-type sequence was used as a negative 
control; disruption of G4 formation was confirmed by ECD in the presence of 100 mM KCl 
with and without 40% MeCN (data not shown). Similar to wild-type, the presence of co-
solvents each increased the stability of G4s containing 5-hmC modifications as well. 
Mod1 was enhanced from 68 °C with 10 mM KCl to 80 °C with MeCN and 77 °C with 
PEG (Figure 3-3A). VEGFmod2 does not form a strong structure, and a parallel orientation 
is only pronounced when KCl, MeCN, or PEG were added (spectra not shown). Melting 
temperatures increased from 68 to 84 and 74 °C upon MeCN and PEG additions 
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compared to KCl control, respectively. Mod3, like mod1, increased stability from 67 °C to 
80 °C with MeCN and to 74 °C with PEG. Interestingly, upon the addition of 100 mM KCl, 
mod2 (TM of 76 °C) is the only modification that decreased melt temperatures compared 
to wild-type (TM of 84 °C) (spectra not shown). Thus, 5-hmC modifications existing on 
cytosines between guanine runs 1 and 2 (mod1) as well as runs 3 and 4 (mod3) contribute 
to increased structure stability (Figure 3-1A).  
EMSA was used to determine inter- vs. intra-molecular G4 structure formation 
(Figure 3-3B). The knockout sequence mentioned above was used here as a linear 
reference in order to indicate G4 migration patterns. Similar to VEGF1-4, the 5-hmC-
modified G4s displayed downward shifts from the knockout reference, KO, suggesting 
the existence of intramolecular species. Further migration is seen when 100 mM KCl is 
added, however, the shift is not marked coinciding with ECD data previously described. 
When 40% MeCN is added, slower migration of each sequence displays banding above 
the corresponding control and 100 mM KCl samples. VEGFmod1 upon 100 mM KCl and 
40% MeCN addition exemplifies intermolecular structures which may be correlated to the 
decrease in slope of the thermal stability profile shown in Figure 3-3A. This decrease in 
slope signifies an increase in the number of isoforms existing which may include a cohort 
of inter- and intra-molecular G4 species combined. Besides mod1, no other sequence 
allowed for intermolecular species. Instead they closely resembled wild-type. Collectively, 
it can be concluded that 5-hmC modifications existing on cytosines involved in loop 
formation do not impair the stability of G4s. 
  
31 
 
  
Figure 3-2. Determination of co-solvent concentrations needed for 
maximum VEGF1-4 formation. 0-100 mM gradient of KCl was added to 
wild-type VEGF G4 to determine 10 mM KCl to be the minimal 
concentration affecting G4 formation markedly. Similarly, 0-40% of 
MeCN or PEG gradients, in 10% increments, were added to wild-type 
resulting in 30% MeCN and 10% PEG being identified for further study. 
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It was then questioned how these epigenetic modifications impact interactions 
between G4-stabilizing small molecules and the structure. To date, there are two 
hypotheses on how small molecules stabilize G4s. First, it is believed that compounds 
envelope the G4 by binding above and below the structure, involved in π-π stacking, and 
intermingling with G4 loops. The second hypothesis suggests G4-stabilizing agents 
intercalate the G4 between tetrads. Because the first has been more widely adopted, we 
investigated whether 5-hmC modifications may hinder small molecule G4 drug discovery 
approaches. 
Utilizing the universal G4-stabilizing cationic porphyrin, TMPyP4 (Figure 3-4A), for 
increased G4 thermal stability, any changes were monitored by ECD (Figure 3-4B). 10 
μM TMPyP4 (2 equivalents to DNA) was used to allow possible stacking above and below 
the VEGF G4 with and without modifications present. TMPyP4 increased wild-type and 
mod1 G4 stability by approximately 12 °C. Compared to wild-type, mod1 had enhanced 
stability by 7 °C in the presence of TMPyP4. This was not the case for mod2 or mod3 
which did not change compared to their respective controls. This suggests that epigenetic 
modifications can influence G4 drug discovery efforts using small molecules. 
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Figure 3-3. Co-solvents mildly increase thermodynamic stability of modified 
intramolecular VEGF structures. 30% MeCN and 10% PEG increase thermal 
profiles of each modification as compared to their own control (10 mM KCl) (A) 
EMSA shows decreased isoforms in wild-type VEGF than with modifications. 
Mod1, unlike the others, allows intermolecular G4 formation, as well as, 
intramolecular (B) 
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Table 3-2. TM of VEGF modification sequences. 
 
VEGF1-4 VEGFmod1 VEGFmod2 VEGFmod3 
10 mM KCl 67 68 68 67 
10 mM KCl + 30% MeCN 83 80 84 80 
10 mM KCl + 10% PEG 77 77 74 74 
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Figure 3-4. 5-hmC modifications increase small molecule effect on G4 thermal stability. 
Universal G4-stabilizing agent, TMPyP4 (10 μM) (A), enhances VEGF G4 formation, 
decreases the number of isoforms, and increases thermodynamic stability when 
epigenetic modifications are present on nucleotides involved in loop formation (B) 
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Table 3-3. TM of VEGF modifications with TMPyP4. 
 
VEGF1-4 VEGFmod1 VEGFmod2 VEGFmod3 
10 mM KCl 63 70 71 70 
10 mM KCl + 10 μM TMPyP4 75 82 71 71 
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3.3. Using Co-Solvents to Mimic Physiological Conditions for Drug Discovery Screening 
Proto-oncogene MYC is amplified in approximately 80% of cancer cases 
(cBioPortal) (Dang et al. 2006). Its protein functions as a transcription factor and is 
responsible for regulating more than 15% of genes within the human genome (Chung & 
Levens 2005). It plays a significant role in cell proliferation, growth, differentiation, and 
apoptosis (Eisenman 2001). Thus, its deregulation frequently results in tumorigenesis. 
The c-myc promoter contains a nuclease hypersensitivity element (NHEIII1) upstream 
from two proximal promoters that initiate 100% of gene transcription (Siddiqui-Jain et al. 
2002; Seenisamy et al. 2004). This element contains a guanine dense sequence of 31 
bases that can form a G4. This predominantly parallel G4 can act as a silencer of 
transcription and has been a popular target for G4 drug discovery programs (Figure 3-5) 
(Brooks & Hurley 2010; Brooks & Hurley 2009). However, with many failed classes of G4-
stabilizing compounds, the current G4-stabilizing agent screening approaches need to be 
optimized by considering the intracellular conditions of a cell’s nucleus. Upon 
consideration, the conditions can be mimicked outside of a cell and applied within 
screening to best predict the small molecule/G4 DNA interactions occurring in biological 
systems. 
 Through the use of co-solvents, physiological mimicry can be accomplished 
outside of cells. The nature of a nucleus being dehydrated and crowded can be achieved 
with a myriad of osmolytes and molecular crowding agents. To investigate this use of co-
solvents, a small cohort of co-solvents was chosen to add to MYC G4 oligonucleotide 
sequences (Table 3-2) prior to G4 induction. Osmolytes MeCN, glucose, sucrose, and 
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ethylene glycol along with their corresponding polymers and molecular crowding agents 
PEG, dextran sulfate, glycerol, and ficoll were utilized. Preliminary studies with these co-
solutes weeded out ethylene glycol, as it prevented stable, inducible G4 formation as 
observed with ECD (data not shown). However, no other problems arose. Along with co-
solvent use, we incorporated another way to mimic nuclear conditions more ideally by 
extracting nucleoplasm from MiaPaCa-2 cells. This extracted nucleoplasm contains all 
co-solutes within the nucleus existing outside of DNA and proteins. Each condition was 
first used to examine any effect on MYC G4 thermal stability by ECD (Figure 3-6A & B). 
 Three concentrations of extracted nucleoplasm were used to induce MYC G4 
formation under relevant physiological conditions (Figure 3-6A). The highest 
concentration (10%) increased the number of isoforms existing as seen by an increase in 
slope of its melting profile, but it also shifted the spectra from parallel G4 formation to 
favoring more ssDNA forms (maxima at 270 nm). This effect was not seen in the presence 
of 2 or 5% nucleoplasm as these greatly resembled 10 mM KCl control. Similarly, we 
compared co-solvents to 10 mM KCl control (Figure 3-6B). The concentrations for co-
solvents were determined by examining the ECD spectra for the minimum concentration 
of co-solvent needed to achieve maximal G4 formation as described earlier with VEGF 
(data not shown). The final concentrations used were 20% MeCN, 20% PEG, 20% ficoll, 
10% dextran sulfate, 10% glycerol, 10% glucose, and 20% sucrose. Of these, we 
observed likenesses between all co-solvents except PEG and MeCN which were 
destabilizing by 9 °C and stabilizing by 14 °C, respectively. Along with resembling control, 
these co-solvents were comparable to 2 and 5% nucleoplasm addition as each decreased 
the number of isoforms existing compared to control as shown by an increase in slope 
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(ficoll by 74%, dextran sulfate by 78%, sucrose by 48%, glucose by 68%, and glycerol by 
48%). Knowing this, the influence on inter- vs intra-molecular isoforms predominating was 
next evaluated. 
 A knockout G4 oligonucleotide was used as a linear reference for EMSA (Figure 
3-6C). This sequence contains G>T mutations in each of the guanine runs (I-IV) involved 
in G4 formation. Upon KCl, nucleoplasm, or co-solvent addition, the prime species 
existing were intramolecular isoforms based on the lower migration patterns. Crisp 
banding was observed in 2 and 5% nucleoplasm samples compared to 10 mM KCl 
control, and the co-solvents that best mimicked this were MeCN, dextran sulfate, ficoll, 
glycerol and glucose. There are greater amounts of isoforms when 10% nucleoplasm, 
PEG, and sucrose are present. Cooperatively, this suggests that 2 or 5% nucleoplasm, 
MeCN, dextran sulfate, ficoll, glycerol, and glucose can mimic physiological conditions of 
a cell’s nucleus and limit the amount of G4 isoforms existing. With this, we then wanted 
to use them in a blind small molecule drug discovery screen. 
 Förster, or fluorescent, resonance energy transfer (FRET) melt was utilized with a 
DNA probe containing a fluorophore on the 5’ end and a quencher on the 3’ end. This 
DNA probe consisted of the MYC G4 forming sequence, and upon G4 induction, the 
fluorescence signal is quenched as the fluorophore and quencher are closer together as 
opposed to its linear form. Compared to a buffer control, stronger G4 thermal stability is 
indicated by a decrease in fluorescence, an increase in G4 formation, and an increase in 
melting temperature before returning to its linear state. This is performed blind in 96-well 
plates and is normally executed under simple buffer or KCl conditions.   
40 
 
  
Figure 3-5. The biologically 
relevant MYC G4. This model 
depicts a tri-stacked parallel G4 
containing guanine runs I-IV and 
harboring 1:2:1 loop lengths from 
5’3’ (Adapted from Brooks & 
Hurley 2010). 
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Table 3-4. MYC oligonucleotide sequences. 
MYCKO 
5’GCGCTTATGTTGAGTGTGTTGAGTGTGTTGAAGGTGTTGAGG
AGAC3’ 
MYCKO EMSA 5’[6~FAM]GCGCTTATGTTGAGTGTGTTGAGTGTGTTGAAGGTGT
TGAGGAGAC3’ 
MYC 5’GCGCTTATGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGA
GGAGAC3’ 
MYC EMSA 5’[6~FAM]GCGCTTATGGGGAGGGTGGGGAGGGTGGGGAAGGT
GGGGAGGAGAC3’ 
MYC FRET 5’[6~FAM]GCGCTTATGGGGAGGGTGGGGAGGGTGGGGAAGGT
GGGGAGGAGAC[TAMRA~6~FAM]3’ 
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Figure 3-6. Co-solvents and extracted nucleoplasm to induce physiologically 
relevant average G4 topology. 2 and 5% nucleoplasm stabilizes and 
decreases the number of G4 isoforms existing (A) most co-solvents are similar 
to control except PEG and MeCN which destabilize and stabilize the G4, 
respectively (B) EMSA depicts intramolecular G4 formation with each co-
solvent approach with decreased isoforms existing with 2-5% nucleoplasm, 
MeCN, dextran sulfate, ficoll, and glucose (C) 
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 We applied this same method under three separate conditions (buffer, KCl, and 
KCl+MeCN) using a single 96-well plate of various compounds ranging from known G4 
stabilizers and destabilizers, as well as, novel agents synthesized or isolated at the 
University of Mississippi (Figure 3-7). The hit rate for lead compounds was 36% in the 
control (buffer) run and decreased to 26% upon 10 mM KCl and 20% MeCN addition. 
Many differences in G4 stabilizing compounds were seen between each plate, and not all 
stabilizing agents within the MeCN run were observed under the more simplistic 
conditions. These lead compounds were validated by ECD analysis, and only two 
compounds seemed to favor ssDNA forms as opposed to G4 (SN-38 and EC-2014-13) 
(Figure 3-8). Thus, utilization of co-solvents decreased the hit rate in compound screening 
and yielded high success in ECD confirmation. Future studies will investigate cellular 
effects and the mechanism of action of these lead compounds described. 
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Figure 3-7. FRET melt drug discovery application of co-solvent MeCN. The same 96-well 
plate was screened in control, KCl, and KCl+MeCN conditions to examine any differential 
hits. This “in house” plate consists of known pan-G4-stabilizing agents, as well as various 
natural products and molecules isolated or synthesized at The University of Mississippi. 
The screening rate for positive compounds decreased by 10% from control to KCl+MeCN 
addition. Lead compounds with G4-stabilizing effects are seen in red while blue wells 
indicate G4-destabilizing agents. White wells depict compounds with no effect on G4 
stability. 
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Figure 3-8. Validation of MeCN FRET melt lead compounds. Some compounds 
(SN-38 and EC-2014-13) shifted G4 formation to ssDNA, but all other 
compounds increased G4 formation and thermal stability compared to 10 mM 
KCl control. 
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3.4. Discussion 
 G4s have been described to putatively form within promoter and 5’ UTR regions 
throughout the genome, primarily in oncogenes and tumor suppressor genes (Verma et 
al. 2008; Chambers et al. 2015). This localization around the TSS was conserved 
amongst four different species (mouse, rat, chimpanzee, and human). In vivo evidence 
of G4s existing within cells by observing localization of a G4 structure specific antibody, 
BG4, found G4s within telomeres and non-telomeric regions in nuclei and in cytoplasmic 
regions—most likely RNA (Biffi et al. 2013). DNA G4s, specifically promoter G4s, have 
gained much attention for novel targets for anti-cancer therapeutics. 
 Using G4s as molecular targets for cancer is related to their prevalence within 
oncogenes and tumor suppressor genes that are highly dysregulated in an array of cancer 
types. This was found in a genome wide sequence analysis in 2015, but even amongst 
the initial characterization of promoter G4s within MYC, cancer therapeutics was a central 
focus. The two most studied promoter G4s are MYC and VEGF, which both form tri-
stacked structures with parallel loop configurations. MYC is highly deregulated in about 
80% of cancers, and VEGF is frequently overexpressed resulting in angiogenesis, tumor 
cell proliferation, invasion, and metastasis. Many attempts have been made to suppress 
MYC and VEGF activity independently, but most have failed. Interestingly, each of the 
G4s in these promoters function as transcriptional silencing elements. Thus, stabilizing 
these structures could lead to breakthroughs in cancer research.  
 Most G4 targeting is centralized around small molecules that selectively bind and 
stabilize specific structures since globular formations are better targets for selectivity 
compared to dsDNA. Screening for small molecules that stabilize specific G4s is usually 
47 
 
performed by a FRET melt screen. This procedure is implemented under simple 
conditions containing buffer and the presence of a monovalent cation like potassium with 
KCl. This practice has led to the identification of several compound classes that act as 
G4 stabilizers, but the biological application has not yielded high success. To date, one 
compound succeeded in vitro and initial in vivo models leading towards the clinic. 
Quarfloxin failed phase II due to high albumin binding. This is but one example of failed 
agents for G4 drug discovery, as most are not successful in cells and are not dependent 
upon a G4 mechanism of action. There are various factors that come into play for drug 
screening outside of cells such as affinity, selectivity, and specificity. We were primarily 
concerned with the imitation of the molecular conditions within a cell, more specifically, in 
this case, within a cell’s nucleus in order to recapitulate G4s formed in the nucleus. This 
led to the current application of co-solvents as mimicry agents of biomolecules within a 
cell’s nuclear environment, as well as the investigation of epigenetic modifications that 
occur within CpG islands of genes whose promoter regions contain G4-forming regions. 
 Biomolecules influence cellular activities, as they occupy a substantive amount of 
space within a cell. These biomolecules allow for the dehydrated and condensed 
environment within nuclei. MeCN and PEG are common co-solutes reported in G4 
literature. Some conclude that PEG positively impacts G4 melting behavior by stabilizing 
the structure directly as opposed to altering the environment (Corradini et al. 2012; Spink 
& Chaires 1999). Thus, careful consideration needs to be taken when proposing to use 
PEGs as molecular crowding agents which led to the alternative agents utilized herein 
(dextran sulfate, ficoll, and glycerol). Similar criticism has been made regarding the use 
of MeCN, but it has since been accepted to not alter G4 conformations, but to enhance 
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G4 stability by manipulating the surroundings (Zhou et al. 2016). Herein we included other 
osmolytes (sucrose, glucose, and ethylene glycol). Additionally, extracted nucleoplasm 
was introduced within these studies as an ideal example of mimicking physiological 
conditions, which is a practice that has not been performed within the G4 field to date. 
 With this array of co-solutes, we determined the optimal concentrations to be used 
within MYC (and VEGF) in order to understand how biomolecules affect G4 formation in 
order to improve future drug discovery efforts. We concluded that low amounts of 
extracted nucleoplasm, MeCN, dextran sulfate, ficoll, glycerol, and glucose can limit the 
number of intramolecular G4 isoforms existing when compared to simple buffer +/- KCl 
controls. Collectively, we distinguished that the effect concentration of co-solutes has on 
G4 formation differs for each promoter structure, as the amounts used with MYC and 
VEGF were not identical. In other words, the co-solutes that decrease MYC isoforms did 
not necessarily decrease VEGF isoforms. This is particularly significant when utilizing co-
solvents for mimicking physiological conditions outside of cells during drug discovery 
screens, as conditions cannot be uniformly applied. 
 In this work, we utilized MeCN during FRET melt screens for lead compounds 
stabilizing the MYC G4. Using the same 96-well compound plate, we observed a 10% 
decrease in lead compounds with 10 mM KCl + 20% MeCN added (23%) compared to 
the buffer control plate (43%) and KCl alone (44%). Additionally, the lead compounds did 
not each coincide from plate to plate with varying conditions. Interestingly, a previously 
described MYC G4-stabilizing compound, quindoline i (sample C10, Figure 3-7), 
increased G4 thermal stability by 26 °C in the control plate, 33 °C in the 10 mM KCl plate, 
yet destabilized the G4 by about 4 °C in the presence of 10 mM KCl + 20% MeCN. When 
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first described, quindoline i bound and stabilized the MYC G4 in vitro and expressed anti-
cancer activity via decreased cell proliferation and down-regulation of MYC in 
hepatocellular carcinoma cells (Ou et al. 2007). However, it was later reported that the c-
myc repression was not due to the G4-dependent mechanism (Boddupally et al. 2012; 
Brown et al. 2011). This finding occurred through the use of RAJI and CA46 Burkitt’s 
lymphoma cells, which contain high levels of MYC expression, and the exon test, which 
validates whether a compound’s mechanism is G4 dependent. Briefly, the two lymphoma 
cells differ by a translocation between the MYC gene and an immunoglobin gene. RAJI 
cells contain the translocation which retains both exons 1, 2, and 3, and the promoter 
containing the MYC G4-forming region. On the other hand, CA46 cells lost the 
endogenous promoter by reciprocal translocation and only contains exon 2, and 3. 
Therefore, monitoring the expression of exon 1 and 2 in RAJI cells should match, whereas 
exon 1 is related to the G4 in CA46 cells and exon 2 is driven by the Ig promoter. It is 
significant that our FRET melt screen findings on quindoline i match the previous literature 
both in identifying it as a “hit” in simple buffer conditions and by removing it as a “hit” in 
the nuclear recapitulating conditions. Future studies will evaluate lead compounds (IA 16-
1, IA 31.3.1, and CM361) from the 10 mM KCl + 20% MeCN plate consistent for anti-
cancer activity in RAJI and CA46 cells, along with being subjected to the exon test.  
50 
 
  
Figure 3.9. G4-forming sequences likely to contain 
5-hmC modifications. Fewer 5-mC modifications 
occur in G4-forming regions while 5-hmC density is 
co-localized with putative G4s in 100 bp windows 
centralized around the TSS. There exists a high 
density of G4s having 5-hmCs downstream from 
the TSS, in promoter regions. (Adapted from 
Bhavsar-Jog, Van Dornshuld, Brooks, et al. 2014). 
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 Epigenetic modifications are another set of physiological factors that may affect 
the stability of G4s. These modifications could be methylation, hydroxymethylation, or 
acetylation (Bestor 2000). Each have roles in regulating transcription depending on the 
location and type. Cytosines are the nucleotides susceptible to generating epigenetic 
modifications, specifically on the 5th carbon atom. Cytosines have a higher chance of 
being modified when the base is adjacent to a guanine (CpG dinucleotides), commonly 
termed a CpG island. Such sites are found in almost half of all promoters in the human 
genome (Taberlay & Jones 2011; Hoffman & Hu 2006; Antequera & Bird 1993). DNA 
methylation is the most common occurring epigenetic modification and has gained 
attention for contributing to cancer phenotypes, investigating the roles that methylated 
CpG islands have during cancer development is critical (Bestor 2000; Taberlay & Jones 
2011; Sharma et al. 2009).  
 Recently, the methylation status on G4s has been analyzed as to how it impacts 
Bcl-2 promoter activity (Lin et al. 2013). Within the Bcl-2 proximal promoter there lies a 
CpG island, and methylation of this region led to increased G4 stability which markedly 
reduced DNA elongation within a PCR stop assay. Lin et. al. claim that methylating the 
cytosines involved in the Bcl-2 G4 not only increased thermodynamic stability of the 
structure but also shifted the mixed loop orientation into a more pronounced parallel one. 
This suggests that the methylated G4 is more likely to keep its conformation rather than 
unfold which would enhance an inhibitory effect on gene expression. Interestingly, our 
work suggests that the hydroxymethylation of a CpG island within the VEGF promoter 
region does not impair or enhance G4 stability but allows the formations of similar stable 
and inducible parallel G4s as wild-type. However, it is important to note that G4-forming 
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regions within promoters are more likely to contain 5-hmC than 5-mC modifications 
(Figure 3-9) (Halder et al. 2010; Bhavsar-Jog, Van Dornshuld, Brooks, et al. 2014). 
Previous literature described epigenetic modification-containing CpG islands in 
induced pluripotent stem cells and endothelial stem cells where they modulate gene 
expression (Stroud et al. 2011). Endothelial stem cells play key roles in vasculogenesis 
and angiogenesis, as they form the lining of blood vessels. VEGF  is overexpressed by 
tumors during both processes in order to increase oxygen levels and provide essential 
nutrients (Turunen & Ylä-Herttuala 2011; Kim et al. 2009; Davis-smyth 2016). It is 
commonly found upregulated in cancer, mediating tumor growth, invasion and 
metastasis. Here, we investigated the G4-forming region within the cis-element on the 
VEGF promoter which has previously been identified as a novel anti-angiogenesis target 
for cancer therapeutics (Sun et al. 2005; Kim et al. 2016; Agrawal et al. 2013; Sun et al. 
2011; Marušič et al. 2013). The G4-forming sequence contains a CpG site, so for drug 
discovery purposes, it is necessary to explore physiological factors, like epigenetic 
modifications, that can occur in CpG islands that may affect G4 formation and stability 
(Yoshida et al. 2016). Thus, G4 stability can be influenced by methylation and possibly 
hydroxylation depending on the promoter. 
 With the increasing evidence of G4s existing throughout the genome and within 
cells, the understanding of the biological function and interactions of secondary DNA 
structures is necessary to establish (Biffi et al. 2013; Chambers et al. 2015; Huppert & 
Balasubramanian 2006; Lipps & Rhodes 2009; Murat & Balasubramanian 2014). Such 
non-canonical structures can affect gene expression, but the regulation behind this 
function remains in question. Herein, we observed the effects of 5-hmC modifications on 
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the VEGF G4 and learned that such modifications do not impact overall G4 formation but 
alters stability in the presence of a stabilizing compound. This suggests that drug 
discovery efforts should consider the presence of epigenetic modifications on the G4 of 
interest to consider all potential biological interactions. Also, future studies are necessary 
to investigate whether protein or transcription factor binding to G4s containing 
modifications is impeded as is seen with small molecules. Such studies will aid in the 
understanding of a proposed mechanism behind gene regulation via epigenetic 
modifications and biomolecules, as well as, further expand G4 drug discovery and 
research programs to include other disease states like Parkinson’s disease, Alzheimer’s 
disease, Fragile X Syndrome, and ALS. 
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CHAPTER 4. CHARACTERIZING AND TARGETING THE KRAS G4
4.1. Introduction 
 Over the past decade, pancreatic cancer rates have increased while 5-year 
survival rates remain steadily in the single digits at around 7% (SEER Cancer Statistics, 
2015). This malignant disease accounts for 3% of all cancer incidences within the United 
States; it can readily grow and metastasize throughout the body, and is likely to avoid 
detection for a marked amount of time, due to the location of the pancreas (American 
Cancer Society, 2015). Treatment options are limited as most diagnoses occur well after 
the cancer has metastasized. A great deal of effort has gone into identifying risk factors 
associated with the disease, such as smoking, obesity, and diabetes. Unfortunately, none 
of these considerations have led to earlier detection or have markedly changed survival 
rates, to date. However, one main factor that researchers are centrally focused on is 
genetics and the gene mutations, whether inherited or acquired, that may be causative to 
pancreatic cancer. Out of those being researched, one oncogene seems notable, kRAS. 
The RAS gene family consists of five proteins—kRAS, nRAS, hRAS, mRAS, and 
rRAS—each of which are responsible for encoding intracellular membrane-bound G-
proteins involved in cell growth and apoptosis through the Raf-MAP kinase pathway 
(Lavrado et al. 2015; Saad et al. 2014). The RAS genes are structurally similar and share 
high homology (approximately 85%) in exon sequences (Friday & Adjei, 2005). Classical 
RAS proteins—kRAS, nRAS, and hRAS—are located on the short arm of their respective 
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chromosomes 12, 1, and 11 while rRAS and mRAS are located on the long arms of 
human chromosomes 19 and 3, respectively. Normally, the encoded p21RAS protein is in 
one of two states; a GDP-bound inactive state and a GTP-bound active state. In its active 
state, RAS stimulates the association of RAF to the membrane where kinases can then 
phosphorylate and activate RAF. Following this event, RAF activates MEK which, in turn, 
initiates ERK to signal for other substrates allowing for the regulation of cell growth and 
survival (Wilson & Tolias 2016). 
A single point mutation can convert the RAS genes into an oncogenic form, 
resulting in p21RAS locked into its active form causing aggressive cell growth, metastasis, 
and anti-apoptosis. Mutations within RAS occur most often at residue 12, 13, or 61, and 
are prevalent in oncogenesis. RAS protein, rRAS, does not cause malignant 
transformations like the others in the subfamily (Vähätupa et al. 2016). The most common 
mutation for kRAS occurs at residue 12 and is seen in 30% of all cancers (majority being 
solid malignancies) including lung, pancreatic, and colon (Lowy & Willumsen 1993; 
Ostrem & Shokat 2016). Mutation of nRAS at position 61 is often seen in melanoma and 
myeloid leukemia, mutants of mRAS typically occur on residues 22 or 71 and are found 
in breast cancers, and, lastly, frequently expressed in bladder cancer, hRAS mutations 
happen at either residue 12 or 61 (Ward et al. 2004). 
In pancreatic ductal adenocarcinomas alone, mutated kRAS is overexpressed in 
over 90% of patients (Bailey et al. 2016, cBioPortal for Cancer Genomics). To date, many 
approaches to suppress mutated RAS protein activity have been tried, but no therapeutic 
option has yielded specific inhibition in clinical trials. If kRAS expression could be 
suppressed, then cancerous cell proliferation that is addicted to mutant protein activity 
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would cease, and the cell could no longer evade apoptosis (Lavrado et al. 2015). This 
makes the approach of regulating gene expression through transcriptional control an 
attractive therapeutic focus. 
Many attempts have been made to inhibit mutant Ras signaling. However, the 
approaches tried in these trials failed pre-clinically and clinically. Decreasing levels of 
GTP-bound RAS seemed promising in order to disrupt the constitutively active RAS 
protein. However, RAS has high affinity for GTP (approximate Kd = 10-11 M) and there is 
a high concentration of GTP within the cell (approximately 0.5 mM), which makes 
substrate competition improbable (Ostrem & Shokat 2016). Antisense approaches to 
block translation of the RAS protein decreased tumorigenicity within mice, but the 
oligonucleotides lacked a safe and effective drug delivery when applying to human 
patients (Gray et al. 1993). Some tried to transport the antisense oligonucleotides in viral 
vectors or plasmids, but there was still no success in tumor specific drug delivery (Zhang 
et al. 1993; Aoki et al. 1997). 
Other studies focused on inhibiting kRAS membrane localization or targeting the 
protein’s downstream effectors. Since Ras proteins are small and hydrophilic, they must 
undergo four stages of post-translational modifications in order to bind to the intracellular 
membrane (Ghobrial & Adjei 2002; Adjei 2001; Cho & Lee 2002). Researchers found that 
farnesyl protein transferase inhibitors block the first step of Ras modifications, thus 
blocking membrane localization (Queneau et al. 2001; Rowinsky et al. 1999; End 1999). 
Currently, the approach having the best success involve inhibition of RAS effector 
signaling. Raf serine/threonine kinases are critical drivers of Ras-mediated oncogenesis 
through the interactions and activation of MEK1/2 and ERK1/2. Rigosertib is in phase III 
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clinical trials and works by indirectly inhibiting RAS through blocking the RAS-binding 
domains of RAS effectors (Ostrem & Shokat 2016; Athuluri-Divakar et al. 2016; Cox et al. 
2015). This compound shows great promise in vitro, but there may be issues with efficacy 
in patients.  
Besides working on the Raf-MEK-ERK pathway, others have looked at inhibiting 
parallel pathways like PI3K-AKT-mTOR. PI3K inhibition has previously shown partial 
regression of tumor growth in a lung cancer murine model harboring upregulated kRAS 
(Ebi et al. 2011; Castellano et al. 2013; Gupta et al. 2007). However, other evidence 
suggests that this pathway is not a significant effector for RAS signaling (Engelman et al. 
2008). Though approximately 53 PI3K-AKT-mTOR inhibitors and 29 Raf-MEK-ERK 
inhibitors are currently in clinical trials, these small molecules are not promising as a 
monotherapy for cancers harboring mutant RAS (Cox et al. 2015). Preclinical evaluation 
of possible synergistic activity between these inhibitors may have more promising results 
(Britten 2013). Many of these anticancer drugs have not passed clinical trials due to their 
lack of specificity and selectivity for mutant kRAS, as well as, causing the activation of 
parallel pathways resulting in tumor growth and disease progression (Adjei 2001).  
In order to gain specificity and selectivity, immunological approaches have been 
utilized to differentiate between wild-type and mutant kRAS. Because mutated kRAS can 
be classified as being tumor specific, a synthetic peptide technique was used to target 
cytotoxic T-cells to tumors expressing the altered protein where p21RAS already 
underwent membrane localization (Gjertsen & Gaudernack 1998). Successful peptide 
delivery resulted in T-cell response to p21RAS and allow the recognition and killing of tumor 
cells harboring mutated RAS. This posed some difficulties as T-cells require full activation 
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via multiple signals, and the kRAS mutation was found to be poorly immunogenic which 
resulted in ineffective vaccinations (Fossum et al. 1995; Gjertsen et al. 2001).  
Recently, small molecule approaches to target mutant kRAS via the kRAS-SOS 
binding pocket has yielded promising results (Wilson & Tolias 2016). Stephen Fesik’s 
research group at Vanderbilt University has synthesized compounds that bind to the 
GDP-bound kRAS mutant G12D through the use of fragment-based screening (Sun et al. 
2012). Lead compounds were shown to weakly bind the kRAS binding pocket initiating a 
change in protein structure and opening up a new binding pocket. Blocking this binding 
pocket prevents kRAS-SOS interactions and does not allow for kRAS to initiate its 
downstream signaling cascade. However, further optimization of these compounds is 
needed to gain the necessary affinity required to move the compounds into clinical trials.  
Another team is looking at small molecules that irreversibly bind to kRAS G12C 
through direct targeting of the cysteine mutation (Ostrem et al. 2013). The fragments 
utilized covalently modify the cysteine and bind to the switch-II region on kRAS causing 
decreased cell viability and increased cell death for lung cancer cell lines harboring the 
mutation when compared to cells with wild-type kRAS. Unfortunately, the compounds 
have limited potency to move from preclinical to clinical trials. Based on these 
approaches, suppressing kRAS expression has shown preclinical promise, but no viable 
molecular target has yet been established. 
To tackle this “holy grail” of cancer therapeutics, we focused on an alternative 
method to target kRAS involving regulating gene expression through transcriptional 
control via secondary DNA structures, G-quadruplexes (G4s). This approach will 
ultimately decrease protein expression and thus halt kRAS protein activity and likely 
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cause apoptosis of the addicted cancerous cell. This not only is a unique approach to 
cancer therapeutics, but it will expand promoter G4 drug discovery programs into 
examining kRAS as a target for pancreatic cancer therapeutics. We hypothesize that 
unique G4s in the kRAS promoter will have biological functions and may serve as 
molecular targets for anti-cancer development. To investigate this hypothesis and overall 
tactic, we focused on two specific aims allowing us to determine the biologically relevant 
kRAS G4 structure, characterize compounds with the G4-stabilizing potential, identify the 
major structure present with compound-induced stabilization, and to examine the 
mechanism of action of such agents in pancreatic cancer cells. 
Specific Aim 1. Elucidate the predominant and biologically relevant G4 isoform 
within the kRAS promoter region. 
Specific Aim 2. Identify and characterize kRAS-mid-G4-stabilizing compounds in 
vitro and in cell culture. 
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4.2. Form and Function of Multiple G4s in the kRAS Promoter 
The region of the proximal promoter in the kRAS gene from -324 to -39 bp, in 
relation to the transcriptional start site (TSS), contains a high density of guanine residues 
(Figure 4-1A). The three distinct guanine runs have potential to form multiple G4 isoforms 
that can act as silencing elements (Lavrado et al. 2015). One has been previously studied 
resulting in the finding of numerous isoforms (Cogoi & Xodo 2006; Xodo et al. 2008; Cogoi 
et al. 2008; Cogoi et al. 2009; Paramasivam et al. 2011). The molecular models of G4 
32R portray di- and tri-stacked tetrads with conflicting loop sizes and directionality. The 
first 2 isoforms characterized were parallel tri-stacked G4s harboring a kinked cytosine 
loop connecting the first and second guanine runs (Cogoi & Xodo 2006). Under further 
examination, this model was proposed to contain a thymine in the second run instead as 
suggested by Cogoi et al. 2008. Next, a model arose containing the kinked thymine in the 
second guanine run with an inclusion of T/G (Paramasivam et al. 2011; Paramasivam et 
al. 2009). Further examination of 500 bp upstream of the TSS exposed the previously 
described G4 and two uncharacterized G4-forming regions. 
We refer to the known 32 bp sequence as the near region, capable of forming the 
G4near, sitting -128 bp from the TSS. Labeled based on their proximity to the TSS, the 
near (-129 to -161), mid (-174 to -226), and far (-238 to -273) regions have been identified 
as capable of forming G4s based on the consensus pattern (G3N1-9)3G3 (Figure 4-1A) 
(Morgan et al. 2016). This work focuses on elucidating the predominant G4s that form 
within the kRAS promoter, understand any biological role in gene regulation, and targeting 
such structures with small molecules for pharmacological intervention in pancreatic 
cancer therapeutics. All oligonucleotides used are described in Table 4-1.  
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G4 formation and overall thermal stability was assessed by ECD in the absence 
and presence of G4-stabilizing KCl (100 mM) alone or combined with 40% acetonitrile 
(MeCN) (Figure 4-1B). G4near formed all parallel configured isoforms, as depicted by the 
positive Cotton effect at 262 nm in KCl with or without MeCN, which has been formerly 
observed in literature (Bari & Pescitelli 2010). Thermal stability was increased from 46 °C, 
in buffer only, to 59 °C with KCl present, and to 69 °C with the addition of MeCN. G4mid 
forms a mixed parallel and antiparallel structure as examined by two positive maxima at 
263 and 290 nm, respectively. Upon KCl addition to buffer only, thermal stability improved 
from 56 to 82 °C, and increased to >95 °C with the addition of 40% MeCN. Unlike the 
others, the far region does not form higher order structures, as ECD spectra only notes 
spectral maxima indication possible parallel and antiparallel conformation with KCl and 
MeCN combined. Additionally, these G4s did not form strong enough to determine 
thermal stability.  
Total knockout sequences were created for each G4-forming region by G>T 
mutations (Table 4-1). G4 formation was disrupted as observed by ECD in the presence 
of 100 mM KCl as predicted (Figure 4-1C). Such sequences were used as linear species 
controls in EMSA. 
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Table 4-1. kRAS oligonucleotide sequences. 
G4near-KO 5’AGGGCTTTTTGGGAAGAGTGAAGAGGGGGAGG3’ 
G4near-KO EMSA 5’[6~FAM]AGGGCTTTTTGGGAAGAGTGAAGAGGGGGAGG3’ 
G4near 5’AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG3’ 
G4near EMSA 5’[6~FAM]AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG3 
G4mid-KO 5’CGGGGAGAAGGAGTTTGCCGGGCCGGGCCGGCGGGGGAGG
AGCGTTTGCCGGGC3’ 
G4mid-KO EMSA 5’[6~FAM]CGGGGAGAAGGAGTTTGCCGGGCCGGGCCGGCGGG
GGAGGAGCGTTTGCCGGGC3’ 
G4mid 5’CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGGAG
GAGCGGGGGCCGGGC3’ 
G4mid EMSA 5’[6~FAM]CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGG
GGGAGGAGCGGGGGCCGGGC3’ 
G4mid DMS 5’[6~FAM]TTTTTTTCGGGGAGAAGGAGGGGGCCGGGCCGGGC
CGGCGGGGGAGGAGCGGGGGCCGGGCTTTTTTT3’ 
G4mid FRET 5’[6~FAM]GCGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCG
GGGGAGGAGCGGGGGCCGGGC[TAMRA~6~FAM]3’ 
G4mid DMS Forward 
Primer 
5’-[6~FAM]GATGCGTTCCGCGCTCGA-3’ 
G4mid DMS Reverse 
Primer 
5’-[6~FAM]AGTCCCTCCTCCCGCCAA-3’ 
Mut A 5’CGTTGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGGAG
GAGCGGGGGCCGGGC3’ 
Mut B 5’CGGGGAGAAGGAGGTGGCCGGGCCGGGCCGGCGGGGGAG
GAGCGGGGGCCGGGC3’ 
Mut C 5’CGGGGAGAAGGAGGGGGCCGTGCCGGGCCGGCGGGGGAG
GAGCGGGGGCCGGGC3’ 
Mut D 5’CGGGGAGAAGGAGGGGGCCGGGCCGTGCCGGCGGGGGAG
GAGCGGGGGCCGGGC3’ 
Mut E 5’CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGTGGAG
GAGCGGGGGCCGGGC3’ 
Mut F 5’CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGGAG
GAGCGGTGGCCGGGC3’ 
Mut G 5’CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGGAG
GAGCGGGGGCCGTGC3’ 
G4far-KO 5’AAGGTGTGGCTGTTGCGGTCTAGTGTGGCGAGCCGTGCC3’ 
G4far-KO EMSA 5’[6~FAM]AAGGTGTGGCTGTTGCGGTCTAGTGTGGCGAGCCGT
GCC3’ 
G4far 5’AGGGGTGGCTGGGGCGGTCTAGGGTGGCGAGCCGGGC3’ 
G4far EMSA 5’[6~FAM]AGGGGTGGCTGGGGCGGTCTAGGGTGGCGAGCCGG
GC3’ 
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Figure 4-1. Three potential G4-forming regions within the kRAS promoter. The proximal 
promoter region on the kRAS gene highlighting three G4-forming regions: near, mid, and 
far (A) ECD spectra of kRAS G4-forming regions in buffer only (solid line) with the addition 
of 100 mM KCl (long dash line) and with 100 mM KCl + 40% MeCN (short dash line) (B) 
Total G-to-T mutations (denoted in A by asterisks) prevent G4 formation (C); these 
mutated sequences were used in EMSA as linear references to show the formation of 
inter- or intramolecular structures in the presence of buffer alone, 100 mM KCl, or 100 
mM KCl + 40% MeCN. Reduced isoforms of intramolecular G4s forming in near and mid 
regions were observed, especially upon 40% MeCN addition (D) (Adapted from Morgan 
et.al., 2016) 
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In order to differentiate between inter- and intra-molecular G4 formations, 
electromobility shift assay (EMSA) was employed (Figure 4-1D). The total knockout 
sequences described above were used as reference for the migration of linear species. 
Faster migration compared to linear strands verifies the formation of compact G4 
structures. With KCl present, a downward shift migration is observed for G4near and G4mid. 
An even greater shift occurred with the further addition of 40% MeCN. In all, ECD and 
EMSA data indicate that the G4far region is not likely to form stable intramolecular G4s, 
as compared to the stable and inducible structures note in G4near and G4mid. 
Structure elucidation and confirmation of G4near was performed in Dr. Brooks’ 
laboratory by Dr. Vanessa Gaerig, in order to clarify the predominant G4 (data not shown); 
several varying structures have been reported previously (Cogoi et al. 2008; Cogoi & 
Xodo 2006; Paramasivam et al. 2011; Paramasivam et al. 2009; Cogoi et al. 2009). 
Radioactive DMS footprinting with the 32-nucleotide near kRAS promoter region and two 
G>T mutant sequences was performed. In the presence of 100 mM KCl, the predominant 
G4 forming within the wildtype sequence contains three guanine runs that are continuous 
(A, C, and E) and one discontinuous, or kinked, run (B). G-to-T mutation of run B disrupted 
G4 formation while mutation of run D preserved the guanine protection pattern noted in 
wildtype. Collectively, ECD spectra and DMS footprinting supports the formation of a tri-
stacked structure harboring a 1:1k:1:12 parallel loop conformation (k refers to a single 
“kinked” thymine in run B between guanines). This data coincides with one of the 
previously proposed models depicting a kinked higher order structure (Paramasivam et 
al. 2009). 
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Unlike G4near, G4mid has not been previously described. This 54-nucleotide region 
within the kRAS promoter consists of seven runs of contiguous guanines, referred to as 
runs A-G from 5’3’ (Figure 4-2A). DMS footprinting was executed in the absence and 
presence of 100 mM KCl on the whole wild-type sequence. Banding patterns were 
described by histogram using ImageJ software, and this evidence suggests several 
species of G4mid exist in equilibrium with partial protection patterns observed in runs B, E, 
and F (Figure 4-2B). 
Mutant sequences were created within each of the seven guanine runs to help 
characterize G4mid. Each mutated run contained critical G>T mutations in order to disrupt 
G4 formation when specific runs of guanines are required. We observed such disruption 
by ECD spectra (Figure 4-3) and thermal analysis in 10 mM KCl, 10mM KCl + 20% MeCN, 
and 100 mM KCl (Figure 4-2C, Table 4-2). All G4 structures formed maintained the mixed 
loop orientation (Figure 4-3) similar to that observed in wildtype (Figure 4-1B). Amongst 
all conditions, G4 destabilization was evident when runs B, E, and F were mutated as 
thermal stability was markedly decreased in all conditions. Thus, from ECD analysis and 
DMS footprinting, the major isoform model proposed herein is a tri-stacked structure 
consisting of runs B, C, E, and F having intervening loops of 2, 10, and 8 nucleotides from 
5’3’, respectively (Figure 4-2D). 
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Table 4-2. TM of G4mid sequences (Morgan et al. 2016). 
 Wild-type Mut A Mut B Mut C Mut D Mut E Mut G Mut F 
10 mM KCl 70 65 50 63 65 63 53 65 
10 mM KCl + 20% MeCN 73 70 64 71 71 64 64 71 
100 mM KCl 81 78 70 89 82 84 63 87 
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Figure 4-2. Elucidation of G4mid G4 topology. DMS footprinting of G4mid with 
100 mM KCl. Full protection is seen in guanine runs B, E, and F; partial 
protection in runs A, B, C, E, F, and G; no protection seen in run D (A) Full 
sequence fluorescent DMS sequencing gel with no KCl control and 100 mM 
KCl (B) thermodynamic stability of various G>T mutations that disrupt 
guanine runs A-G (C) proposed topology of G4mid as a tri-stacked G4 with 
runs B, C, E, and F with a 2:10:8 loop configuration in the 5’3’ direction 
(D) (Morgan et al. 2016). 
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Figure 4-3. G4 topology of kRAS mutated sequences under 
variant co-solvent conditions. Full G>T mutations were made 
in each of the seven runs of guanines within the kRAS mid-
region sequence on the promoter. ECD spectra showed no 
effect on topology in any of the mutated sequences compared 
to wildtype. Each sequence showed a mixed 
parallel/antiparallel configuration as denoted by positive 
Cotton effects around 265 and 290 nm, respectively. 
69 
 
 
Next, we wanted to evaluate the biological function of G4s within the kRAS promoter. 
Previous literature noted transcriptional silencing of kRAS in the presence of cationic 
porphyrin and known G4 stabilizing agent, TMPyP4 in Panc-1 (pancreatic 
adenocarcinoma), HCT116 (colon cancer), and SW620 (colorectal adenocarcinoma) 
cells (Cogoi et al. 2008; Lavrado et al. 2015). FRET melt studies tested the effect of this 
compound on thermal stability of both G4near and G4mid (Figure 4-4A). G4near increased 
from 34 to 65 °C, and G4mid alone was 52 °C heightening to 73 °C. In contrast, we used 
TMPyP2, a constitutional isomer of TMPyP4, as a negative control because it does not 
interact with G4s. As predicted, TMPyP2 had no effect on thermal stability for G4near and 
decreased that of G4mid by 6 °C. To test these compounds’ effect on cell survival and, 
more specifically, the effect on regulating kRAS, we used the pancreatic cell line Panc-1. 
These cells are mildly addicted to their kRAS mutation and are commonly used in studies 
on kRAS (Lieber et al. 1975; Cogoi & Xodo 2006; Cogoi et al. 2013; Lavrado et al. 2015). 
The MTS assay was utilized to measure cell viability in the presence of TMPyP2 or 
TMPyP4 from 0-500 μM for an incubation time of 48 hr. These compounds have an 
absorbance at 490 nm which is the same as the formazin measured through the MTS 
assay. Thus, in order to deduct this colorimetric contribution from the background, we 
measured absorbance of matched doses of compound before (pre-wash) and after 
removing (post-wash) and replacing all media from the plates (Figure 4-4B, performed by 
Dr. Tracy Brooks). Post-wash conditions showed little-to-no effect on cell viability while 
pre-wash conditions showed a dose-dependent decrease in survival likely due to the 
colorimetric contribution of the compound and over-estimation of decreased cell viability 
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post-subtraction (only by approx. 25% with TMPyP4 and no effect with TMPyP2). From 
this data, we moved forward with compounds at concentrations of 25 and 50 μM. 
 kRAS mRNA expression was monitored by qRT-PCR in Panc-1 cells upon 25 μM 
TMPyP4 or TMPyP2 incubation for 48 hr (Figure 4-4C, performed by Dr. Tracy Brooks). 
Our findings show that TMPyP4 significantly decreased kRAS expression (p<0.05) by 
45% compared to expression from untreated control. As expected, TMPyP2 did not 
change kRAS mRNA expression. Thus, this evidence supports the idea that silencing of 
kRAS expression is mediated by G4 stabilization. 
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Figure 4-4. TMPyP4-induced G4 stabilization on pancreatic cancer cell viability and 
kRAS expression. TMPyP4, but not TMPyP2, markedly stabilized G4near and G4mid as 
examined by FRET melt (A) Cell viability in Panc-1 cells showed decreased survival when 
compound was not washed (pre-wash) from plate and replaced with fresh media. This 
can be related to the colorimetric contribution of TMPyP4 causing an over-estimation of 
reduced cell viability after washing away the compound (post-wash) (B) Panc-1 cells were 
treated with either 25 μM TMPyP2 or TMPyP4 for 48 hr, and kRAS mRNA expression 
was examined, as normalization to GAPDH, TMPyP4 significantly (*p<0.05, as 
determined by one-way ANOVA with Tukey post-hoc analysis) decreased promoter 
activity and, ultimately, kRAS mRNA expression (C) (Morgan et al. 2016). 
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 Next, we wanted to assess which G4 is responsible for the silencing effect on kRAS 
transcription. A panel of luciferase promoters were constructed to examine the kRAS full 
promoter and isolated G4 regions (Figure 4-5A). All plasmids were assembled by 
inserting the regions of interest within the kRAS promoter into the multiple cloning region 
(MCR) of a promoterless pGL4.17 firefly luciferase vector (EV). The kRAS-500 plasmid 
was built containing the promoter from -500 to +0 from the TSS amplified by PCR from 
human genomic DNA which was previously described to inhabit G4 elements (Song et al. 
2009; Lavrado et al. 2015). Another plasmid was constructed by Eurofins Operon 
containing the -324 to +50 bp region, with respect to the TSS. This region has been 
reported significant for full promoter activity and contains the near, mid, and far G4-
forming regions (Jordano & Perucho 1988; Matsuo & Yamazaki 1989; Yamamoto & 
Perucho 1988). This plasmid was used to derive two mutated plasmids that contained G-
to-T mutations in either the G4near (termed 324 mt Near) or the G4mid (termed 324 mt Mid) 
regions through site-directed mutagenesis; G-to-T mutations were made to each region 
like those in the knockout oligonucleotides in Table 4-1 and Figure 4-1C. The 
promoterless, empty vector (EV) and promoter-driven SV40 plasmids were used as 
negative and positive controls, respectively. 
 Basal expression was first examined from each plasmid after 48 hr transfection in 
HEK-293 cells, where firefly activity was normalized to Renilla luciferase expression 
driven by pRL. The fold RLU for EV activity was 0.03 ± 0.01, SV40 activity was about 50-
fold higher than EV with 1.46 ± 0.08, and the kRAS plasmids were somewhere in between 
the two controls; the kRAS promoter plasmids were not significantly different from the 
others (kRAS-500: 0.69 ± 0.11 and kRAS-324: 0.94 ± 0.16 fold RLU). HEK-293 cells were 
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transfected with each of the plasmids and treated with either 25 µM TMPyP2 or TMPyP4 
for 48 hr (Figure 4-5C). TMPyP2 did not cause any significant effects with any of the four 
plasmids, and TMPyP4 did not affect EV (1.14 ± 0.21 fold RLU) or SV40 (1.01 ± 0.03 fold 
RLU) controls. Significant decreases in promoter activity were seen with TMPyP4 
exposure to the kRAS-500 (0.69 ± 0.07 fold RLU) and kRAS-324 plasmids (0.61 ± 0.1 
fold RLU). Because the G4-forming regions are contained within the kRAS-324 plasmid, 
this plasmid was chosen to pursue further studies as described above. 
 Site-directed mutagenesis allowed us to introduce G>T mutations within the near- 
or mid-G4 forming regions to ensure G4 formation was inhibited. We used the number of 
G>T mutations to minimize disruptions to transcription factor binding sites. Basal 
expression of these new plasmids was elucidated after 48 hr of transfection; no marked 
differences were noted amongst each of the plasmids (Figure 4-5D). When compared to 
kRAS-324 (0.94 ± 0.16), fold RLU of 324 mt Near was 1.31 ± 0.23, and 324 mt Mid was 
0.96 ± 0.30. Like before, treatment with TMPyP2 did not bring about any significant 
changes to promoter activity with any of the plasmids, whereas both 25 and 50 µM 
TMPyP4 did (Figure 4-5E). The higher concentrations of TMPyP4 showed decreases in 
luciferase activity with both EV and SV40 plasmids. This dose-response may be due to 
the background effects of TMPyP4 by reducing luciferin glow due to the dark color. Thus, 
any dose-response related decrease of promoter activity was compared to the effects on 
non-G4 promoters by using a two-way ANOVA. Significant decreases (p<0.05) in 
promoter activity were observed in kRAS-324 upon 50 μM TMPyP4 treatment (26% 
decrease, 0.55 ± 0.09 fold RLU) and 324 mt Near (30% decrease, 0.51 ± 0.15 fold RLU) 
plasmids. 324 mt Mid showed a 21% increase in RLU, as compared to EV and SV40, and 
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it was 0.89 ± 0.14. Therefore, the crucial player for transcriptional silencing within the 
kRAS proximal promoter is most likely the G4mid higher order DNA structure, as promoter 
activity is suppressed when G4mid is stabilized with TMPyP4. Unlike G4near, this new 
molecular structure is an ideal target for therapeutic development and rational drug 
design.
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Figure 4-5. G4-mediated silencing is contained within the mid-
region. Four plasmids were constructed using a promoterless 
empty vector (EV) pGL4.17 backbone to observe which regions 
within the kRAS promoter drive silencing activity (A) Basal 
expression of non-mutated plasmids showed no significance 
between each other but does compared to EV (*p<0.05) and to 
SV40 ($p<0.05) by one-way ANOVA (B) Addition of 25 μM TMPyP2 
and TMPyP4 to HEK-293 cells showed TMPyP4 being equally 
significant for each plasmid compared to untreated control 
(#p<0.05, as determined by one-way ANOVA) (C) Basal expression 
of kRAS-324 plasmid series harboring specific G4-knockout 
mutations for the near or mid regions showed no significant change 
in expression compared to wild-type (D) A dose response of 
TMPyP4 (25 μM and 50 μM) was examined in kRAS-324 and the 
mutated plasmids. By a two-way ANOVA, both kRAS-324 and 324 
mt Near were significant in decreasing promoter activity (^p<0.05, 
as compared to EV and SV40). Because 324 mt Mid did not cause 
silencing, these observations suggest the G4-mediated silencing 
to be contained within the G4mid region (E) (Morgan et al. 2016) 
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4.3. Elucidation of G4mid in Physiological Conditions 
With G4mid determined to be the biologically relevant structure in the above studies, 
we next looked to characterize G4 formation while mimicking the physiological conditions 
of a cell’s nucleus. The intranuclear conditions are dehydrated water makes up 
approximately 60% of the solution mass along with extremely crowded with biomolecules 
(Cui et al. 2013). Biomolecules are important as they possess functions within living cells 
and inhabit 20-40% of the nucleus’s volume. With this, we used a series of co-solvents to 
introduce these conditions to our G4 samples. The chosen co-solvents are neutral 
polymers polyethylene glycol (PEG), dextran sulfate, ficoll, and glycerol for molecular 
crowding and the corresponding monomers acetronitrile (MeCN), glucose, and sucrose 
as osmolytes. We incorporated both high and low mass polymers to increase net packing 
efficiency (Sharp 2016).  
Along with these co-solvents, we utilized extracted nucleoplasm from MiaPaCa-2 
cells to most likely mimic the nuclear conditions of a cell. We observed an increase in 
stability towards the mixed parallel/anti-parallel topology of G4mid with 10 mM KCl upon 
the addition of 2, 5, and 10% nucleoplasm (Figure 4-6A). Thermal stability increased from 
37 °C to 57.5, 70.7, and 100 °C, respectively. With 2% nucleoplasm present, the number 
of isoforms decreased as the slope increased by 5.4% as compared to the 10 mM KCl 
control. Upon the addition of 5 or 10% nucleoplasm, negligible changes in slope were 
observed, compared to control. These lower concentrations (<10%) of extracted 
nucleoplasm were used in ECD studies, as 40 and 100% concentrations resulted in 
masking background on the Olis ECD instrument. The higher concentrations were used 
for EMSA studies where it was evident that there was a marked increase in the number 
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of isoforms present (Figure 4-6B). As compared to the linear knockout reference, G4mid 
forms intramolecular structures as noted by the downward migration pattern seen with 
KCl alone, as well as with each concentration of nucleoplasm; we observed an increase 
in the number of G4 isoforms existing as the amount of nucleoplasm increased. 2, 5, and 
10% nucleoplasm each show crisp banding, similar to KCl alone, while 40 and 100% 
samples express more isoforms present with lighter and more dispersed banding patterns 
visible. Thus, we utilized lower concentrations, specifically 2 and 5%, of extracted 
nucleoplasm for the remainder of our studies. 
The co-solvents were then characterized in order to determine the lowest 
concentrations (ranging from 0-40% at 10% increments) necessary for maximal G4 
formation by G4mid. By ECD spectral analysis we elucidated the saturation point in which 
this effect occurred for each co-solvent in the presence of 10 mM KCl (Figure 4-7). The 
saturating concentrations determined were 20% MeCN, 40% PEG, 20% ficoll, 20% 
glycerol, 10% glucose, 20% dextran sulfate, and 20% sucrose (Figure 4-8A). As 
compared to the 10 mM KCl control, these concentrations of co-solvents increased G4mid 
thermal stability by 24, 59, 17, 19, 20, 21, and 21 °C, respectively. A majority of co-
solvents each markedly increased the slope, seen in the melting spectra in Figure 4-8A 
(MeCN by 141%, ficoll by 158%, dextran sulfate by 93%, and sucrose by 4,473%).  
Next, we looked to compare and contrast the co-solvent ECD data with that of 2 
and 5% extracted nucleoplasm (Figure 4-8B). In the case of 2% nucleoplasm, 20% MeCN 
closely resembled the same melting profile having no effect on thermal stability and 
increasing the slope, thus decreasing the number of G4mid isoforms, by 57%. With 5% 
nucleoplasm, other co-solvents held similar thermodynamic properties. With no effect on 
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thermal stability, 20% glycerol and 10% glucose had slight increasing effects on slope by 
27 and 22%, respectively. Most of this ECD data is confirmed by EMSA in Figure 4-8C. 
Compared to linear control, knockout, G4mid forms intramolecular structures when co-
solvents are present, with the exception of PEG, glucose, and sucrose. These three co-
solvents resulted in intermolecular structure formation, as seen by the upward migration 
as compared to the KCl control. It is important to note that with inter- and intra-molecular 
G4 formation occurring, there is also banding coinciding with knockout migration 
indicating that the samples contained linear forms of the oligonucleotide as well. 
Collectively, the osmolyte MeCN and crowding agent glycerol seem to be promising co-
solvents to move forward with in elucidating the predominant biologically active isoform 
of G4mid. 
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Figure 4-6. Using nucleoplasm as idealized solvent for 
physiological G4 formation. 2, 5, and 10% nucleoplasm 
increase G4mid formation and increase thermal stability. 2% 
nucleoplasm decreases the number of G4 isoforms present 
compared to control based on percent change of the Hill Slope 
(A) Electromobility shift assay describes intramolecular G4 
formation with varying amounts of nucleoplasm. 2 and 5% 
nucleoplasm addition decreases the number of isoforms 
present compared to 40 and 100% (B). 
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Figure 4-7. Determination of minimum concentration of co-solvent needed for 
maximum G4 formation. 0-40% gradients of various co-solvents, in 10% 
increments, were added to kRASmid. 20% MeCN, 40% PEG, 20% ficoll, 10% 
glucose, 20% dextran sulfate, 20% glycerol, and 20% sucrose allowed for 
maximal formation of G4mid. 
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Figure 4-8. Comparing co-solvents to nucleoplasm. ECD spectra and melting 
profile of all co-solvents tested (A) 5% nucleoplasm and 20% sucrose share 
similar thermal profiles while 2% nucleoplasm has a markedly steeper slope 
than control or any co-solvent addition (B) EMSA shows decreased isoforms 
with nucleoplasm and MeCN compared to KCl. Most co-solvent additions led to 
intramolecular structure formation, but PEG, glucose, and sucrose caused 
intermolecular structures (C) 
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4.4. Targeting G4mid with Small Molecules 
Characterizing the structure and average topology of the biologically active G4mid 
aids in G4 drug discovery efforts for kRAS. To identify small molecules to selectively 
stabilize G4mid, a blind screen by FRET melt was performed for over 1,600 compounds 
from National Cancer Institute (NCI) Diversity Set III. Lead compounds from each 96-well 
plate were logged and were all repeated on the same plate to eliminate false positives 
(Figure 4-9). This assay utilizes a FRET probe that contains the G4mid region with a FAM-
labeled fluorophore on the 5’-end and a TAMRA quencher on the 3’-end. G4 formation 
will bring the fluorophore and quencher together resulting in decreased fluorescent signal 
compared to the linear counterpart when the G4 does not form or unfolds. When 
screening small molecules, lead agents may have a decrease in initial fluorescence and 
will show an increase in melting temperature as they enhance thermodynamic stability of 
G4 formation. 
 FRET melt studies yielded 4 hit compounds that were moved forward for validation 
by ECD: NSC 317605, 106506, 274905, and 44750. ECD analysis was executed for both 
G4mid and G4near to understand the compound selectivity (Figure 4-10A). NSC 317605 did 
not change the number of isoforms for G4near or G4mid; it moderately increased thermal 
stability of G4near by 9 °C and markedly enhanced G4mid stability by 18 °C. The 
compounds NSC 106506, 274905, and 44750 modestly destabilized G4near by 5, 3, and 
4 °C, respectively, and pronouncedly affected G4mid with decreased melting temperatures 
of 10, 6, and 5 °C, respectively.  
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Figure 4-9. FRET melt repeat of lead NCI compounds. Over 1,600 compounds from the 
NCI Diversity Set III were blindly screened by FRET melt. This 96-well plate shows the 
replicate of lead compounds suggesting approximately 7 hits based on melting 
temperature (red wells). Compounds exhibiting increased temperature changes greater 
than 5 °C are considered G4-stabilizing (red wells) agents while those decreasing melting 
temperature by greater than 5 C are G4-destabilizing (blue wells). 
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HEK-293 cells underwent a 48 hr transfection and treatment with 1 μM of each 
compound in EV and kRAS-324 plasmids. Though not all compounds affected G4 stability 
for either structure, each small molecule did significantly downregulate promoter activity 
in kRAS-324 (FL) compared to EV negative control and DMSO treated cells (Figure 4-
10B). Compared to DMSO, the fold RLU showed NSC 106506 decreased promoter 
activity by almost 90% (0.089 ± 0.122), NSC 44750 by 73% (0.265 ± 0.078), NSC 274905 
by 70% (0.299 ± 0.001), and NSC 317605 by 65% (0.345 ± 0.065). Collectively, from 
ECD and luciferase, the lead compound to pursue as a G4mid stabilizer and potential 
kRAS down-regulator further is NSC 317605, as it markedly reduces promoter activity 
and stabilizes G4mid greater than G4near (Figure 4-10C). 
FRET melt was used to differentiate selectivity of 6 compounds over 3 G4s: G4mid, 
G4near, and MYC (Figure 4-11A). The test compounds included the cationic porphyrins, 
TMPyP2 and TMPyP4, with known properties for having no effect on stability and for 
stabilizing pan-G4s, respectively. These positional isomers act conversely as TMPyP2 
does not impact G4 structures and TMPyP4 increases stability of all G4s non-selectively. 
The other 4 compounds tested share pharmacophore properties, such as a 4-ring 
aromatic structure and amine substitution. Also, NSC 176327 and 338258 are both 
ellipticines. The first report of quindoline i showed its ability to stabilize the MYC G4 while 
having anti-cancer activity in Hep G2 hepatocellular carcinoma cells (Ou et al. 2007). 
However, later it was understood that this inherent cytotoxicity was not dependent on the 
MYC G4 mechanism (Brown et al. 2011; Boddupally et al. 2012). Since then, quindoline 
i remains a G4 stabilizing compound effecting several structures and not limited to MYC 
with intracellular activities above G4s. NSC 176327 and 338258 were lead compounds 
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from other NCI Diversity Set screens that our lab identified to stabilize G4near and MYC 
G4s, respectively. NSC 338258 was reported as the first G4 selective agent with a 
validated mechanism of action dependent on G4 stabilization (Brown et al. 2011).  
FRET melt studies with this series of compounds displayed different interactions 
depending on the G4 present. As predicted, TMPyP2 does not markedly change the 
thermal stability of each G4. Its isomer, as well as quindoline i, notably stabilized each 
G4 structure, as seen by the right-handed shift in thermal melt profiles (Figure 4-11B). In 
agreement with published studies, NSC 338258 stabilizes MYC and not G4mid or G4near 
(Brown et al. 2011). NSC 176327 did not affect G4mid, but stabilizes both G4near and MYC. 
In contrast, our hit compound from the NCI Diversity Set III, NSC 317605, stabilizes G4mid 
and MYC, but not G4near. From this cohort, NSC 176327 and 317605 remain interesting 
compounds in terms of kRAS G4 drug discovery as they each stabilize only one of the 
two G4s within the kRAS. After transfecting HEK-293 cells with kRAS-324 (FL) promoter 
plasmid, we noted that TMPyP2 and NSC 176327 do not markedly modulate promoter 
activity, but TMPyP4 and NSC 317605 significantly reduces promoter activity by 26% and 
65%, respectively (Figure 4-11C). This further validates G4mid as the primary silencing 
structure within the kRAS promoter. 
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Figure 4-10. NCI lead compounds with G4near and G4mid. Four lead compounds 
from the G4mid FRET melt screen were validated by ECD. NSC 317605 
increased thermal stability greater than the other compounds for G4mid with little 
effect on G4near (A) All compounds decreased promoter activity in kRAS-324 
(FL) as compared to EV (red bars are significant, p<0.01 as compared to DMSO 
treated cells, as determined by a two-tailed t-test) (B) Structure of NSC 317605 
(C). 
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Figure 4-11. G4 stabilizing compounds and their varying selectivity. FRET melt of 
G4mid, G4near, and MYC with an array of G4-interactive compounds (A) show varying 
increases in stability (B) The universal stabilizing agents TMPyP4 and quindoline i, but 
not TMPyP2, broadly increase all G4 stability. NSC 176327 stabilizes G4near and MYC, 
not G4mid, and NSC 317605 stabilizes G4mid and MYC, but not G4near. G4-mediated 
silencing is seen in cells transfected with kRAS-324 and treated with 25 μM TMPyP4 
or 1 μM NSC 317605, but not 25 μM TMPyP2 or 1 μM NSC 176327 (*p<0.05 as 
compared to untreated control, as determined by a one-way ANOVA) (C). 
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Figure 4-12. NSC 317605 and 176327 in pancreatic cancer cells. NSC 176327 is 
more cytotoxic than 317605 in Panc-1 and AsPc-1 cells (A) NSC 317605 decreased 
kRAS mRNA expression, unlike 176327 (*p<0.05, as compared to untreated control, 
determined by a one-way ANOVA) (B). 
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 Next, we measured how each compound impacted cell viability amongst a 
pancreatic cancer cell panel (Figure 4-12A). Panc-1 cells are least addicted to kRAS 
mutation and AsPc-1 are an aggressive form of pancreatic cancer cells harboring a high 
addiction to kRAS mutation. After 24 hr exposure, NSC 317605 had IC50s at 8.3 ± 0.6 and 
11.72 ± 0.1, for Panc-1 and AsPc-1 respectively. NSC 176327 was more cytotoxic having 
72 hr IC50s of 0.4 ± 0.1 for both cell lines. Using these IC50s to treat the cells for 24 hrs, 
qRT-PCR was performed to examine compound effect on kRAS mRNA expression, with 
respect to GAPDH (Figure 4-12B). Compared to untreated control cells, NSC 317605 
significantly decreased kRAS mRNA levels while NSC 176327 had no effect. This further 
supports G4mid as the primary target for kRAS G4 drug discovery. 
 Simultaneously with the previous small molecule screening, we characterized 
compounds submitted by our collaborator Dr. Khondaker Miraz Rahman from King’s 
College in London. We were searching for compounds selective for G4 structures within 
the kRAS promoter, specifically the mid region. The class of triaryl benzofurans examined 
consisted of 23 analogs. Thermodynamic stability was examined for G4mid and G4near 
upon compound addition (Figure 4-13A). Several compounds markedly increased G4mid 
stability over G4near such as KN-119, -159, -212, - 239,-257, and -267 while others acted 
on both G4s (KN-154, -217, -232, -237, -242, -247, and -272. Along with influencing 
thermodynamic stability, many of these compounds decreased promoter activity upon 48 
hr treatment in kRAS-324 transfected HEK-293 cells (Figure 4-13B). These results 
indicate that compounds KN-159, -212, -237, -239, -242, and -272 should move into 
mechanistic confirmation studies using the pancreatic cancer cell line panel mentioned 
above.  
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 Of these six compounds, most did not exhibit cellular cytotoxicity after 72 hr 
exposure in a panel of pancreatic cancer cells at concentrations up to 100 μM. KN-242 
and KN-272 each had a dose-dependent cytotoxic effect on pancreatic cancer cells. KN-
242 had IC50 values of 2 and 11 μM in Panc-1 and MiaPaCa-2 cells, respectively (cell 
viability with KN-242 treatment performed by Dr. Tracy Brooks, Figure 4-14B), and KN-
272 had IC50 values of 2.1, 60, 6, and >100 μM in BxPc-3, Panc-1, MiaPaCa-2, and 
Capan-1 pancreatic cancer cells, respectively. Observation of these compounds with 
ECD showed that in the case of G4mid, the structure topology shifted from predominantly 
parallel to more anti-parallel isoforms (Figure 4-14A). No change in loop directionality was 
examined for G4near. This phenomenon is believed to be caused by the compound 
(structure shown in Figure 4-14D) interacting with the nucleotides contained within the 
G4 loops as it stacks above and/or below the structure. Similarly, KN-272 changes the 
topology of G4mid (Figure 4-15A) and not G4near (data not shown). Next, we determined 
each compounds’ influence on kRAS mRNA expression. KN-242 significantly reduced 
kRAS expression, as well as the expression of other important genes involved in 
tumorigenesis, such as c-myc, ADAM-15, and Bcl-2 (qRT-PCR performed by Harshul 
Batra, Figure 4-14C)). Likewise, KN-272 had no marked impact on kRAS mRNA 
expression in wild-type kRAS cells, BxPc-3, or in kRAS mutated cells, MiaPaCa-2, 
compared to untreated cells (Figure 4-15B). (Figure 4-13 and 4-15A). This data suggests 
that KN-242, not KN-272, should undergo further studies investigating the biologically 
active kRAS G4. 
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Figure 4-13. Triaryl benzofuran compound effect on G4 thermal stability and kRAS 
promoter activity. 23 compounds were screened by ECD to examine changes in 
thermal stability of G4mid and G4near. 13 compounds markedly increased G4mid 
melting temperature compared to control while 7 increased that of G4near (A) 10 
compounds significantly (red bars, determined by ANOVA with Dunnett post hoc 
analysis) decreased kRAS-324 promoter activity, 6 of which stabilize G4mid only 
and 3 that stabilize both G4mid and G4near (B). 
92 
 
.  
Figure 4-14. G4mid topology changes with KN-242. ECD spectra of G4mid 
changing from a predominantly parallel topology in control (solid lines) to a 
predominantly anti-parallel/mixed conformation upon KN-242 addition (dashed 
lines). No change in topology observed in G4near (A) KN-242 is more cytotoxic 
in the mildly addicted to kRAS pancreatic cancer cell line, Panc-1, compared to 
the more addicted, MiaPaCa-2 (B) Significant decreases in mRNA expression 
was seen for kRAS, MYC, and Bcl-2 within both pancreatic cancer cell lines. 
ADAM-15 was also significantly decreased in MiaPaCa-2 cells (*p<0.05, as 
compared to untreated control, determined by 2-tailed student t-test) (C) 
Chemical structure of KN-242 (D) 
93 
 
  
Figure 4-15. Changes in G4mid average topology and kRAS mRNA expression with KN-
272. ECD spectra displays an exchange in topology for G4mid isoforms in the presence of 
KN-272 (blue lines) (A) No significant reduction in kRAS mRNA expression seen at the 
respective IC50s in pancreatic cancer cells BxPc3 and MiaPaCa-2 (B) Chemical structure of 
KN-272 (C) 
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4.5. Discussion 
 Herein, we elucidated a new G4 in the kRAS core promoter by thoroughly 
examining the guanine-rich region that extends approximately 300 bases downstream 
from the transcriptional start site (TSS). Though three putative G4-forming regions 
seemed to exist within this area, only two formed stable inducible structures in different 
buffer solutions, those closest to the TSS. More significantly were our findings regarding 
G4mid being the biologically active structure within cells compared to what was previously 
described in literature as the function of what we termed G4near. Preliminary 
characterization of G4mid suggests a predominant isoform being a tri-stacked mixed 
parallel/antiparallel structure with long loop lengths of up to ten nucleotides and the 
participating guanines are contained within the second, third, fifth, and sixth runs. 
 Extensive characterization work identified key co-solvents to be used while 
inducing G4mid formation by creating physiologically relevant conditions outside of a cell. 
We investigated the use of molecular crowding and dehydrating agents, alongside 
extracted nucleoplasm obtained from cells, in order to narrow the number of isoforms 
existing. This series of experiments suggests that 20% MeCN and 20% sucrose act 
similarly on G4 formation compared to extracted nucleoplasm and decrease the number 
of predominating isoforms. EMSA confirmed the presence of 20% MeCN and 2 or 5% 
nucleoplasm decreased the number of existing G4 isoforms, favoring parallel 
intramolecular structures. 
 The proximal promoter of kRAS is exceeding guanine rich (~75% G/C) and 
consists of the three described G4-forming regions within two nuclease hypersensitivity 
elements (Jordano & Perucho 1988). The region +/- 50 bp both upstream and 
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downstream of the TSS is responsible for transcription initiation while elements further 
upstream, such as the G4-forming regions, can act as silencing elements. Mutation of 
such elements has been reported to change basal promoter activity, but this was not 
observed with mutated G4near or G4mid which coincides with the knowledge of kRAS 
promoter activity being initiated closer to the TSS (Seenisamy et al. 2004; Wang et al. 
2010). 
 Interestingly, our work describes a lack of silencing potential within the near G4-
forming sequence, which goes against previous findings. It was reported that when a co-
transfection of the human kRAS G4near sequence with a mouse kRAS promoter driven 
chloramphenicol acetyl transferase (CAT) plasmid decreased luciferase expression by 
20% upon TMPyP4 treatment, compared to untreated control (Cogoi & Xodo 2006). The 
human and mouse sequences have an approximate 70% homology similarity (Yamamoto 
& Perucho 1988). Like wild-type, a mutant knockout mouse sequence of G4near, increased 
basal expression indicating a silencing effect. This differs from the current study as we 
focused entirely on the human core promoter sequence of kRAS, using the entire core 
promoter with both wild-type and mutant knockouts. Thus, our work is more directly 
relatable to the endogenous state and depicting the biological function of G4near in 
humans; this was not entirely examined previously. Though the findings are dissimilar, 
our conclusion of G4-mediated silencing being contained within the mid-region does not 
go against previous reports of G4s within the kRAS core promoter. For example, within 
the first 500 bases downstream of the TSS, the addition of universal G4-stabilizing agent, 
TMPyP4, was reported to have decreased kRAS promoter activity, which we confirmed 
(Lavrado et al. 2015). The only difference is that we discovered that the silencing effect 
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is contained within the first 324 bases from the TSS, and narrowed it to the mid G4 region 
(-174 to -226 from the TSS). 
 Many studies have been performed looking at the regulation of the overall G4-
forming region within the kRAS promoter. This has been performed through the use of 
protein transfection and G4-decoys that differ from G4s structurally based on locked or 
twisting base modifications. In each of these instances, G4 formation led to the 
transcriptional silencing previously described, but our findings indicate that this event is 
mediated by the formation of G4mid (Cogoi et al. 2008; Paramasivam et al. 2009; Cogoi et 
al. 2010). Notably, it is difficult to perform transcriptional regulation studies for kRAS as 
physical mapping of regulatory binding proteins has not been reported (Jordano & 
Perucho 1988; Yamamoto & Perucho 1988). However, through the use of PROMO virtual 
laboratory and Qiagen Champion ChiP Transcription Factor search portal, there are many 
potential transcription factor binding sites (consensus sequences) that reside within the 
kRAS core promoter, specifically in the G4-forming regions. There are several Sp1 sites 
surrounding the TSS and contained within the near and mid G4-forming regions, as well 
as sites for MAZ, E2F-1, AP-2, p53, and WT1. Knowing this, when considering the current 
studies using G>T mutations made within the near and mid regions, it can be assumed 
that there was disruption of transcription factor binding. These disruptions may have aided 
in the transcriptional silencing we observed, but our work co-transfecting wild-type or 
mutant human kRAS promoter sequence plasmids and TMPyP4 suggests that the G4-
mediated silencing is more likely to occur due to G4mid than G4near. 
 Knowing that G4mid is responsible for the G4-mediated silencing effect on kRAS 
expression, an initial search for G4-stabilizing small molecules was pursued. Utilizing NCI 
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Diversity Set III, the overall rate for positive leads was approximately 0.25% which further 
decreased to 0.0625% upon thermodynamic stability validation using ECD. Compound 
NSC 317605 markedly stabilized G4mid with a lesser effect on G4near, but its selectivity is 
small, as it stabilizes other G4s such as MYC. Using NSC 317605 and the G4near 
stabilizing agent, NSC 176327, our previous findings of the silencing function being 
mediated by G4mid were confirmed by decreases in promoter activity and kRAS 
expression in cells. Several other compounds were screened as well but did not yield 
great success. Future studies will involve synthesizing analogues of NSC 317605 and 
investigating the role on G4mid stabilization and modulating kRAS transcriptional activity 
as performed here. Also, binding affinity and dissociation constants will be examined 
using competition dialysis and SPR, respectively. Similar to the current works, these 
analogues will be screened against several other known G4s like MYC, VEGF, Bcl-2, c-
kit, hTERT, and ADAM-15 (Morgan & Brooks 2016). Lastly, any pharmacophores 
identified will undergo in vivo xenograft models using mice and zebrafish to explore 
efficacy and toxicological profiles, respectively. 
 kRAS is considered a 'holy grail' in terms of discovering targeted cancer 
therapeutics. Despite its clear validation as a therapeutic target, efforts to date have not 
yet yielded a successful clinical candidate. Previous approaches have focused primarily 
on suppressing the signaling pathways downstream from the activated mutant kRAS 
protein, competing with endogenous GTP, or inhibiting localization to the inner membrane 
with farnesyltransferase inhibitors (Ghobrial & Adjei 2002; Adjei 2001; Cho & Lee 2002; 
Queneau et al. 2001; Rowinsky et al. 1999; End 1999). The current studies present a new 
molecular target for drugging kRAS that is markedly different from previous tactics. While 
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transcriptional down regulation of kRAS has been validated as a clinical approach using 
siRNA and antisense RNA, no molecular target exists to mediate this down regulation 
with a small molecule approach (Gray et al. 1993; Zhang et al. 1993; Aoki et al. 1997). 
G4mid within the kRAS core promoter bridges this gap in transcriptional or translational 
approaches to downregulate the oncogene. Transcriptional control via small molecule 
stabilization of non-canonical DNA structures, specifically resulting in down regulation of 
kRAS, has not been formerly done. G4-mediated silencing will prevent continuous cell 
growth mediated by the mutated RAS protein and result in apoptosis. This cell death 
would preferentially occur within cancer cells harboring mutated kRAS or in cases where 
wild-type kRAS is overexpressed, as they are addicted to this oncogene. kRAS is 
dysregulated in almost 30% of all cancers, predominating in pancreatic (>90%), colorectal 
(45%), and lung (35%). Cumulatively, this work will positively impact cancer patients with 
kRAS addicted tumors, and provide a molecular model for development of additional 
therapy options for cancers harboring mutant or upregulated kRAS. 
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CHAPTER 5. TARGETING BCL-2 FOR NEUROPROTECTION 
5.1. Introduction 
Parkinson’s disease (PD) affects seven to ten million people worldwide with one 
million sufferers in the United States alone (Sissi et al. 2011). According to the National 
Parkinson Foundation, approximately 50,000-60,000 citizens of the United States are 
diagnosed each year while many cases remain undetected. After Alzheimer’s, PD is the 
second most common neurodegenerative disease worldwide (van der Heide & Smidt 
2013). It causes serious complications which are the 14th leading cause of death for the 
nation. PD cases are mainly idiopathic and occur with increased age. There is no current 
cure for this disease, and treatment options depend on the symptoms expressed by the 
patient. Common symptoms include tremors, rigidity, bradykinesia, and postural 
instability (van der Heide & Smidt 2013). Treatments are very expensive as medicines 
cost up to $2,500 per year for a single patient and surgery averages around $100,000 
(Paramasivan et al. 2007). Though medication and surgical therapy are utilized, the main 
goal for treating PD is helping the patient live with the disease by focusing on lifestyle 
modifications. Drug discovery efforts focus on attenuation of neuron death even though 
the exact pathogenesis is unknown due to its complexity (Rangasamy et al. 2010). One 
theory that remains is a mitochondrial dysfunction that leads to apoptosis signaling being 
activated resulting in aberrant dopaminergic neuronal cell death (Burbulla et al. 2010). 
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In wild-type animals, cell death phenotype was assessed with overexpression and 
knockout of Bcl-2 genes (Chipuk et al. 2010). It was concluded that a Bcl-2-dependent 
mechanism was behind the cell death signaling with the presence of caspase cleavage. 
The Bcl-2 family of proteins consists of both anti-apoptotic and pro-apoptotic members 
(Hetts 1998). They either promote or inhibit apoptosis by acting as checkpoints prior to 
cytochrome c release by controlling outer mitochondrial membrane integrity. Once 
cytochrome c is released from the intermembrane space of the mitochondria into the 
cytosol and caspases have been activated, anti-apoptotic members of this family can no 
longer prevent programmed cell death from occurring as the balance of proteins has been 
shifted due to apoptotic stress. Though there is no genetic disposition leading to 
increased loss of dopaminergic neurons, a key option for PD drug design and 
development is to inhibit apoptosis with Bcl-2 being a crucial mediator. 
Aberrant Bcl-2 signaling can occur due to targeted gene disruption of Bax leading 
to increased programmed cell death (Akhtar et al. 2004). Shifting the threshold from Bax 
to Bcl-2 has significant potential to halt neuronal degeneration (van der Heide & Smidt 
2013). In transgenic mice overexpressing Bcl-2, select regions of the brain possessed 
neuroprotective effects as there was an excess of living neurons compared to the Bcl-2 
knockout mice which suffered from degeneration of neurons vastly separated in the brain 
(Farlie et al. 1995; Jean-Claude Martinou et al. 1994; Michaelidis et al. 1996). So far, 
targeted delivery options have been experimented with using pathogenic viral vectors to 
transport Bcl-2 fixed plasmids within neuronal cells. However, this delivery is limited due 
to it being an unsafe dosing regimen to convert from mice to humans (Shacka & Roth 
2005). Thus, a novel molecular target for PD therapeutics is needed.  
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 The cell’s protector protein, Bcl-2, was identified after its isolation from B-cell 
lymphoma which suppressed apoptosis and caused oncogenesis. The human Bcl-2 gene 
isolated had a t(14:18) chromosomal translocation that caused the gene to be associated 
with over-activation of lymphoma cells (Tsujimoto et al. 1985). Under normal conditions, 
this gene is regulated by several gene regulatory proteins and transcription factors. The 
gene control region has two promoters, P1 and P2, located 1300 bases apart (Youdim & 
Arraf 2004). P1 is the predominant promoter involved in transcription. Interestingly, this 
promoter region consists of several Sp1 binding sites. Sp1 binding typically occurs on a 
consensus sequence consisting of many guanine and cytosine bases. These G-rich 
regions allow for G4 formation to occur within the Bcl-2 promoter and potentially affect 
transcription initiation (Figure 5-1).  
Stabilizing G4s in promoter regions can activate or suppress transcription initiation 
by blocking specific gene regulatory proteins, transcription factors, and RNA polymerase 
II. Within the Bcl-2 proximal promoter there exists four such structures. G40 overlaps the 
TSS thus blocking RNA pol II binding and causing transcriptional silencing. The biological 
function behind G42 stabilization has yet to be uncovered, but G43 was shown to act as a 
silencing agent. However, our G4 of interest is G41. The gene regulatory protein WT1, a 
product of Wilm’s tumor suppressor gene, binds approximately 27 to 35 base pairs 
upstream of the predominant Bcl-2 promoter and negatively regulates transcription 
(Heckman et al. 1997). WT1 cannot bind to secondary DNA structures such as G4s as it 
can only bind to ssDNA. Thus, we hypothesize that stabilization of this structure with small 
molecules has may prevent WT1 binding and cause upregulation of Bcl-2 transcription 
resulting in neuroprotection. Also, we predict that selective binding and stabilization of the 
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Bcl-2 G41 by specific compounds, such as cannabinoid derivatives, will not only allow 
transcription initiation activation resulting in neuroprotection, but also, have the ability to 
readily cross the blood brain barrier allowing for the penetrance of neuronal cells. This 
unique approach to Parkinson’s disease therapeutics was accomplished by the following 
aims. 
Specific Aim 1. Elucidate the predominant G4 stabilized with cannabinoid 
derivatives and assess transcription initiation potential. 
Specific Aim 2. Demonstrate the in vitro neuroprotective potential of Bcl-2 G4-
stabilizing compounds, and establish the mechanisms of action related to Bcl-
2 in human dopaminergic neuronal cells. 
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Figure 5-1. Complexity within the Bcl-2 promoter. There exist four G4s within the Bcl-2 
proximal promoter region. G40 is a tri-stacked parallel structure located on the TSS having 
a hairpin forming the second loop that acts as a silencing element (Onel et al. 2016). G41 
is immediately downstream from the TSS, acting as an enhancer, and forms tri-stacked 
mixed parallel/antiparallel structures (Dai et al. 2006).G42 is further downstream from the 
TSS forming a tri-stacked parallel structure with an unknown transcriptional mechanism 
(Onyshchenko et al. 2009). Lastly, G43 is the farthest from the TSS and forms a tri-
stacked parallel structure that acts as a transcriptional silencer like G40 (Sun et al. 2014). 
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5.2. Exploring Physiologically Relevant Conditions for Small Molecule Targeting 
 The Bcl-2 promoter is excessively guanine dense with four G4-forming regions 
within 500 bp of the TSS. In 2006, NMR studies described a major intramolecular mixed 
parallel/antiparallel G4, Pu39, to exist from -1457 to -1480 (Dai et al. 2006). A few years 
later, with the use of invading short peptide nucleic acids (PNAs), G4 formation was 
observed in tandem to Pu39 (Onyshchenko et al. 2009). Termed bcl2G4-2, this G4-
forming sequence is 51 bp and located between -1600 and -1633 and has a parallel 
average topology. Following this discovery, another mixed parallel/antiparallel structure, 
p32, was found to form -443 bp upstream from the TSS (Sun et al. 2014). More recently, 
a G4-forming region identified to overlap the TSS (Onel et al. 2016). P1G4 is a parallel 
structure harboring a hairpin loop. Due to the knowledge that these four major G4s can 
form within the Bcl-2 promoter, it suggests that there exists several isoforms of each of 
these structures as well. 
  Based on this complexity within the Bcl-2 promoter, we have labeled the G4s 
based on their proximity to the TSS. G40 is the most recent structure characterized with 
a hairpin loop, G41 is the first Bcl-2 G4 described, G42 was elucidated using PNAs, and, 
lastly, G43 is a mixed parallel/antiparallel structure furthest from the TSS (Figure 5-1) 
(Table 5-1). Based on the number of structures capable of forming, it is hard to predict 
which G4 may be the predominant structure in vivo as there are several other factors to 
consider physiologically that are hard to replicate in vitro like molecular crowding and 
dehydration. 
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Table 5-1. Bcl-2 oligonucleotide sequences. 
G40 5’CGGGCGGGAGCGCGGCGGGCGGGCGGGC3’ 
G41 5’AGGGGCGGGCGCGGGAGGAAGGGGGCGGGAGCGGGGC3’ 
G41 FRET 5’[6~FAM]AGGGGCGGGCGCGGGAGGAAGGGGGCGGGAGCGG
GGC[TAMRA~6~FAM] 
G42 5’CGGGCCAGGGAGCGGGGCGGAGGGGGCGGTCGGGT3’ 
G43 5’GCTGGGGTCCGCGACGGGGTGGGGGCTCCCGGGGAAC3’ 
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 For the investigation of physiologically relevant conditions on Bcl-2 G41, we utilized 
extracted nucleoplasm and a variety of co-solvents. Compared to the 10 mM KCl control, 
the incorporation of extracted nucleoplasm (2, 5, and 10%) led to a significant reduction 
in the number of isoforms existing as the slopes increased  by 17%, 1,292%, and 52%, 
respectively (Figure 5-2A). With this reduction, there was only an increase in G4 stability 
amongst the 10% nucleoplasm samples by roughly 11 °C. Next, minimal concentrations 
of co-solvents were examined that induce maximal G4 formation (spectra not shown). 
Using 40% MeCN, 10% ficoll, 30% PEG, 10% dextran sulfate, 10% sucrose, and 40% 
glucose, we observed an increase in slope upon the addition of dextran sulfate and 
sucrose indicating fewer G4 isoforms (Figure 5-2B). Of these co-solvents, MeCN and 
PEG act as stabilizing agents with 22 and 10 °C shifts, respectively. The remaining co-
solvents had no marked effect on G4 stability as indicated by a temperature change of 
<5 °C as compared to control. 
 With this knowledge, we wanted to narrow the use of co-solvents to those 
comparable to extracted nucleoplasm (Figure 5-2C). Co-solvents ficoll, sucrose, and 
glucose closely relate to 2% nucleoplasm as there is no effect on thermal stability. 
However, sucrose is the only co-solvent with no effect on the number of isoforms existing 
as ficoll and glucose both increase G4 polymorphic nature with a reduction in slope by 17 
and 52%, respectively. 5% nucleoplasm is similar to ficoll, dextran sulfate, sucrose, and 
glucose. Each of these decrease the slope resulting in more isoforms. Lastly, PEG is the 
only co-solvent closely related to 10% nucleoplasm with a 30% reduction in slope. MeCN 
acts as a stabilizing agent to G41 compared to any amount of nucleoplasm, as well as, 
the KCl control as seen in Figure 5-2B. Collectively, 5% nucleoplasm and its related co-
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solvents should be used for further structural elucidation of the predominant 
physiologically relevant G41. 
 Narrowing down the number of G4 species to its physiologically relevant structure 
will aid in drug discovery efforts for G41. Similar to the MYC G4 studies previously 
described, we performed a small molecule screen with FRET melt under three conditions: 
control buffer, 10 mM KCl, and 10 mM KCl + 40% MeCN (Figure 5-3). The screen 
consisted of a wide variety of compounds ranging from known G4-stabilizing agents to 
natural product derivatives isolated or synthesized at the University of Mississippi. The 
same 96-well plate of compounds was used for screening under each of the three 
conditions. There was an 18% reduction in hit rate when comparing the control buffer 
(52%) to KCl + MeCN additions (30%). The lead compounds observed in the presence of 
co-solvent were next validated by ECD (Figure 5-4). 
 Of the six lead stabilizing compounds from FRET melt, two significantly increased 
G41 thermal stability as noted by a >5 °C melting temperature shift. Endocannabinoid 
derivatives EC-2014-01 and E-5-12-21 enhanced thermal stability by 6 and 15 °C, 
respectively, while the other compounds had no effect. Next, these compounds were 
tested against G40 and G43 as these structures possess a known biological role based 
on previous literature, both acting as silencing elements (Sun et al. 2014; Onel et al. 
2016). G40 was destabilized upon addition of each compound except KN-242 which 
yielded no effect on G4 stability. Notably, compounds EC-2015-04, EC-2014-09, and E-
5-12-21 reduced thermal stability by 9, 9, and 11 °C, respectively. G43 was not influenced 
by EC-2014-09 or KN-242, but EC-2014-01 reduced stability by 11 °C while the other 
three compounds prevented the induction of structure formation altogether. Thus, 
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compounds EC-2014-01 and E-5-12-21 act selectively on G41 over its neighbors, making 
them lead compounds for cellular studies to confirm the mechanism of action to be G4-
dependent.  
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Figure 5-2. Extracted nucleoplasm and other co-solutes reduces average topology 
through physiological mimicry. Similar to 10 mM KCl control, 2 and 5% nucleoplasm 
induced stable G4 formation with both decreasing the number of isoforms without 
increasing G4 thermal stability. 10% nucleoplasm decreased the amount of stable, 
inducible G4 formation and increased thermal stability (A) A wide variety of co-solvents 
were utilized to observe any effect on G4 formation compared to 10 mM KCl control. 
MeCN markedly increases G4 formation and thermal stability. PEG, like MeCN, increases 
thermal stability, but shifts G4 formation more toward ssDNA by a maxima around 270 
nm. The other so-solvents closely resemble control (B) When comparing co-solvents to 
nucleoplasm, most co-solutes mimic 2% nucleoplasm (C) 
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Figure 5-3. FRET melt drug discovery application of co-solvent MeCN. The same 96-well 
plate was screened in control, KCl, and KCl+MeCN conditions to examine any differential 
hits. The screening rate for positive compounds decreased from 52% in control to 30% 
upon KCl+MeCN addition. G4-stabilizing compounds are observed in red while blue wells 
indicate G4-destabilizing agents. White wells depict compounds with no effect on G4 
stability. G4-stabilizing small molecules persistent amongst each of the three screening 
conditions are outlined in black boxes. 
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Figure 5-4. FRET melt lead compounds, EC-2014-01 and E-5-12-21, are selective for 
G41 stabilization. FRET melt hits from the MeCN + KCl plate were confirmed with ECD 
analysis in multiple Bcl-2 G4s. Transcriptional silencers G40 and G43 had decreased 
thermal stability in the presence of EC-2014-01 and E-5-12-21. G43 overall formation was 
inhibited by E-5-12-21, EC-2014-09, and EC-2014-03. KN-242 increased the thermal 
stability of G40. G41 had marked increases in thermal stability upon EC-2014-01 and E-
5-12-21 additions. G42 effects were not examined as the biological role in modulating 
transcription remains to be elucidated. 
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5.3. Selective Small Molecule Targeting of G41 over Other Bcl-2 G4s 
 Upon ECD validation, compounds EC-2014-01 and E-5-12-21 were tested for any 
inherent cytotoxicity using the MTS cell viability assay. Neuroblastoma cells, SH-SY5Y, 
were used as a dopaminergic neuron model like previous reports (Storch et al. 2000; 
Zhou et al. 2014; Masci et al. 2015). After 72 hr treatment, neither compound showed 
signs of cytotoxicity up to 100 μM doses (data not shown). 
 Next, each compounds’ impact on promoter activity was evaluated using a Dual-
Reporter Luciferase assay where Renilla luciferase expression was driven by pRL (Figure 
5-5A). Promoter activity was determined by the firefly to Renilla ratio recorded. The Bcl-2 
plasmid used contains the full promoter sequence harboring all four G4-forming regions, 
and we used promoterless plasmid, empty vector (EV), and promoter-driven plasmid that 
does not contain a G4-forming region, SV40, as our negative and positive controls, 
respectively. This assay was performed in both SH-SY5Y and HEK-293 cells. After 24 hr 
transfection in SH-SY-5Y cells, significant increases in Bcl-2 promoter activity was seen 
with 1 μM E-5-12-21 (2.04 ± 0.12 fold RLU) compared to both plasmid controls and to its 
own untreated and DMSO (1.09 ± 0.37 fold RLU) treated cells. Compounds EC-2014-01 
(0.48 ± 0.20 fold RLU) and KN-242 (0.55 ± 0.58 fold RLU) showed no marked effect on 
promoter activity. When performed in HEK-293 cells, marked increases in Bcl-2 promoter 
activity was seen with KN-242 (2.12 ± 0.07 fold RLU) but not with E-5-12-21 (1.24 ± 0.05 
fold RLU) compared to DMSO treated cells (1.05 ± 0.03 fold RLU) (data not shown). This 
suggests that the transcriptional enhancing effect within the Bcl-2 promoter by E-5-12-21 
is specific to neurons. 
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 Compound E-5-12-21 was next tested for having a neuroprotective role against 
chemical stressor and neurotoxin, 6-hydroxydopamine (6-OHDA) (Figure 5-5C). Using 
SH-SY5Y cells, neurotoxicity was induced by 24 hr treatment of 100 μM 6-OHDA (Storch 
et al. 2000). Neuroprotection was tested against this through co-treatment of compound 
E-5-12-21 (3, 10, and 30 μM doses) for 24 hr with 6-OHDA. Bcl-2 mRNA expression was 
observed by qRT-PCR. There was no significant change in Bcl-2 expression compared 
to untreated or DMSO treated cells. This was performed in duplicate, and due to the 
amount of error, more replicates are ongoing.
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Figure 5-5. Endocannabinoid E-5-12-21 increases Bcl-2 activity. After 24 hr co-
transfection and treatment with lead compounds EC-2014-01, E-5-12-21, and KN-242, a 
significant increase in promoter activity was seen upon E-5-12-21 addition compared to 
its own plasmids and DMSO treated cells, and no effect was seen with other compounds. 
Significance was examined by two-way ANOVA with Bonferroni post-test (*p<0.05 
compared to Bcl-2 control and DMSO, #p<0.01 compared to EV and SV40) (A) 
Endocannabinoid E-5-12-21 structure synthesized by Dr. Eric Bow at the University of 
Mississippi (B) E-5-12-21 has no significant effect on Bcl-2 mRNA expression under 
neurotoxic conditions induced by 24 hr treatment of 100 μM 6-hydroxydopamine, 
performed in biological duplicate (C) 
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5.4. Discussion 
 There exist four major G4s that form within the Bcl-2 core promoter encompassed 
within 500 bp of the TSS. Herein, we focused on targeting G41 located immediately 
upstream of the P1 proximal promoter. Though four structures exist, only three have 
known biological functions on transcription. Silencing occurs most frequently as found 
throughout G4 research, but G41 acts as an enhancing element which makes it a novel 
target for anti-apoptotic-induced neuroprotection. 
 In this work, we utilized an array of co-solvents to determine optimal concentrations 
in conjunction with Bcl-2 G41 oligonucleotides to induce maximal stable structure 
formation. These experiments allowed us to gain insight into how biomolecules influence 
G4 dynamics physiologically. From previous work, we observed that co-solute 
concentrations differ depending on the G4 being examined. For example, in our MYC G4 
studies described previously, 20% MeCN was enough to induce G4 formation, but here, 
for Bcl-2 G41, we needed 40%. Similar to MYC, this concentration was applied during 
FRET melt screens for lead compounds stabilizing G41. We observed an 18% decrease 
in “hit” compounds with 10 mM KCl + 40% MeCN added compared to the buffer control 
plate. The same 96-well plate containing compounds was used for each condition, and 
the leads did not all coincide from plate to plate. ECD later confirmed that two compounds 
from the MeCN treated FRET melt plate remained to be lead stabilizing agents for Bcl-2 
G41 over the other G4s existing within the same promoter region. Using these compounds 
to bind and stabilize G41 is an innovative approach to treating PD. 
 Current therapeutics focus on attenuating symptoms for patients suffering from 
PD, as the underlying pathology is unknown. This is particularly disheartening as PD 
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remains the second most common neurodegenerative disease, Alzheimer’s disease 
being the first, with deaths occurring within ten years following the presence of symptoms. 
The only pathophysiology known is that dopamine-producing neurons are depleted within 
the substantia nigra and within the associated nigrostriatal pathway (Katzung et al. 2012). 
This cell death may be genetically due to mutations in α-synuclein causing the production 
of Lewy bodies or in parkin resulting in marked protein degradation (Mattson 2000; Angot 
et al. 2010). On the other hand, dopamine catabolism occurs naturally as adults lose 
approximately 13% of dopaminergic neurons every ten years. Once 80% of such neurons 
are depleted, PD symptoms can arise. Lastly, environmental factors and chemicals may 
induce PD. The best example of a chemical causing PD is MPTP, a precursor to 
neurotoxin MPP+. This toxin gained much attention in the early 1980s as chronic opioid 
users looked to abusing MPPP where MPTP was an unfortunate byproduct (Fahn 1996; 
Youdim & Arraf 2004). MPTP causes permanent PD symptoms and selectively kills 
dopaminergic neurons within the substantia nigra. 
 To combat PD, most therapeutics that are prescribed are to increase dopamine 
(Potenza et al. 2007; Schapira 2007; Allain et al. 2008; Katzung et al. 2012). Sinemet is 
a common drug given to increase dopamine in the brain and not in the periphery (Hauser 
et al. 2008). Amantidine allows cells to generate more dopamine by enhancing its release 
and slowing down reuptake. Another approach is to prevent the destruction of dopamine 
using monoamine oxidase B (MAO-B) inhibitors like Rasagiline or catechol-oxygen-
methyl transferase (COMT) inhibitors like Entacopone (Olanow et al. 2008; Seeberger & 
Hauser 2009; Youdim et al. 2005). Dopamine receptor agonists are also prescribed to 
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give something “like dopamine”. Common drugs agonizing the D2 receptor are 
Bromocriptine and Ropinirole (Pahwa et al. 2007).  
 Besides these methods, ulterior ways to manage motor complications through the 
use of anticholinergics or antihistamines show potential. Lastly, drugs for neuroprotection 
can be administered that do not target symptomatic relief as these previously described 
drugs do, instead, neuroprotective agents aim to block the loss of dopaminergic neurons. 
Ultimately, these agents should slow or even reverse disease progression (Suchowersky 
et al. 2006). The MAO-B inhibitors mentioned above possess antioxidant, as well as, 
some anti-apoptotic activity and have shown clinical improvement of the disease over 7 
years. Similarly, mitochondrial enhancers, creatine and CoEnzyme Q10, showed 
improvement if taken early on. However, anti-apoptotic agents should be the sole focus 
for PD rational drug design as they have a myriad of mechanisms including antioxidant 
activity and mitochondrial enhancement. Hence, the work presented herein focused on 
targeting the gene that encodes anti-apoptotic protein Bcl-2. 
 Our approach to target secondary DNA structures for transcriptional control of the 
Bcl-2 gene using small molecules is unlike other methods used to treat PD. The lead 
compound E-5-12-21 identified in a blind small molecule screen is an endocannabinoid 
synthesized at the University of Mississippi by Dr. Eric Bow. This compound selectively 
stabilizes G41 and has no inherent cytotoxicity within dopaminergic neurons. It 
significantly upregulates Bcl-2 promoter activity in vitro as shown by luciferase. Notably, 
this increase was only seen within our neuron model and not while using HEK-293 cells. 
This selectivity of neurons over other cell types shows great promise for this compound 
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being used as a neuroprotective agent assuming it can easily cross the blood brain barrier 
(BBB). 
 Future studies consist of further neuroprotection studies using E-5-12-21 under 
environmental and inflammatory stressors (serum starvation and H2O2, respectively), 
competition dialysis to determine relative binding affinity for G41, SPR to reveal 
dissociation of the compound to our structure of interest, and, lastly, this validated 
pharmacophore can be administered to PD-induced mice and/or zebrafish for in vivo 
efficacy and toxicological studies. More FRET melt screens may be performed to yield 
additional lead compounds. These additional small molecule screens should include the 
use of nucleoplasm and other key co-solvents like ficoll, dextran sulfate, sucrose, and 
glucose. Structurally, extensive characterization of the physiologically relevant G4 within 
the Bcl-2 promoter can be accomplished with plasmid or in cell DMS footprinting. 
Collectively, these works will positively impact patients suffering from PD and expand 
current G4 drug discovery efforts from cancer therapeutics to including neuroprotection 
as well. 
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CHAPTER 6. CONCLUSION
 Non-B-DNA structures, such as G4s, have shown promise in drug discovery. 
Applying G4 stabilization to transcriptional control of gene regulation in order to suppress 
oncogene expression is promising for cancer and neuroprotective therapeutic 
approaches alike. G4-mediated transcriptional silencing or enhancing is generally due to 
disruption of transcription factor binding due to a change in DNA structure. Stabilization 
of G4s within promoters act as blockades to RNA polymerase and gene regulatory 
proteins. Enhancing G4 formation and stability is therefore potentially therapeutic, and as 
the G4 is more “globular” than traditional dsDNA, small molecules can be more specific 
for these structures. Extracellularly, stabilization can occur by the addition of alkali 
cations, modifying water content, or by integrating molecular crowding. Intracellularly, 
stabilization can be attained pharmacologically by small molecules. Ligand-mediated G4 
stabilization has been a growing drug discovery program since the initial G4 
characterization in telomeres. 
 5-hmC epigenetic modifications are largely found to coexist on CpG islands that 
contain G4-forming regions than its precursor, 5-mC (Bhavsar-Jog, Van Dornshuld, T. a 
Brooks, et al. 2014). Thus, we looked at the possible role such modifications may play on 
G4-forming regions by affecting structure formation and stability. Due to its promoter 
containing CpG islands and the extensive research done on its characterization, the 
VEGF G4 was used as a model (Sun et al. 2005; Guo et al. 2008; Yoshida et al. 2016). 
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We found that regardless of the location of the cytosine, or the loop in which it is contained 
in, there is no significant effect on G4 formation and stability even in the presence of 
monovalent cations, osmolytes, or molecular crowding agents. Lastly, we observed an 
increase in G4 stability with epigenetic modifications upon addition of TMPyP4 compared 
to wild-type.  
 One question that remains is how these modifications, which reside within G4 
loops, influence regulatory protein binding. From there, 5-hmC modifications on the VEGF 
G4 can be incorporated into a plasmid to monitor the effects on promoter activity 
compared to wild-type with and without known G4-stabilizing agents. Upon further 
understanding of epigenetic modifications and G4 formation, stability, and biological 
function, drug discovery efforts can begin in order to identify compounds that bind and 
stabilize wild-type and modified VEGF G4s alike resulting in reduced promoter activity 
and overall inhibition of angiogenesis in tumor cells. 
 Current drug discovery and development efforts for G4s focus on the use of small 
molecules. With these programs, several compound classes have been found to stabilize 
G4s and impact promoter activity in plasmids of the respective gene. However, these lead 
compounds did not always show activity in cells or, more importantly, in vivo. Only one 
compound has been introduced into clinical trials. Thus, this field needs better screening 
methods that coincide with the intracellular conditions of a nucleus to narrow the number 
of lead compounds that yield higher success rates when transitioning from plasmids into 
cells, and, ultimately, into animals and humans. 
 Using the best characterized G4 to date, MYC, we looked at using various co-
solvents and extracted nucleoplasm to accomplish mimicking the environment of a 
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nucleus outside of cells for drug screening. We observed a marked decrease in hit rates 
(10% reduction) from simple buffer conditions to the addition of KCl and osmolytes MeCN. 
Some of the differences in hit rates coincide with previous findings on compounds like 
quindoline i and TMPyP4 (Ou et al. 2007; Boddupally et al. 2012; Izbicka et al. 1999; 
Siddiqui-Jain et al. 2002). The remaining lead small molecules will be analyzed for 
anticancer activity in lymphoma cells, and the mechanism of action (G4-dependent or –
independent) will be determined by qRT-PCR using the exon test (Boddupally et al. 
2012). Lastly, remaining relevant co-solvents will be used in FRET melt screening similar 
to MeCN shown here. Overall, this will enhance the current methods utilized in drug 
discovery and development programs targeting G4s, especially those in complex 
promoters like kRAS and Bcl-2. 
kRAS is one of the leading oncogenes in the cancer research field. It is highly 
deregulated and promotes tumorigenesis in a third of all cancer types, with over 90% 
frequency in pancreatic ductal adenocarcinomas. Several inhibition approaches have 
been attempted including disruption of membrane localization, inhibition of downstream 
effectors, competing with intrinsic GTP, and antisense. Each of these tactics failed, thus, 
there is a critical need for new targets. We identified a novel molecular target within the 
guanine dense kRAS core promoter that has the potential to silence transcription resulting 
in kRAS downregulation and tumor cell death. We conclude that G4mid should be the 
central focus for rational drug design over its non-biologically active neighbor, G4near. 
Utilizing NSC 317605, we observed selective stabilization of G4mid over G4near and 
downregulation of kRAS. Though this compound was not specific for kRAS G4s as it 
stabilizes MYC as well, synthesizing analogues may yield greater specificity and 
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selectivity for G4mid. Upon identification of G4mid-stabilizing agents, anticancer activity and 
the mechanism of action can be validated in a pancreatic cancer cell line panel, colorectal, 
and lung cells, as well as, in primary patient biopsies of the same cancer types. These 
models will represent both mutant forms of kRAS and tumor cells where kRAS is 
upregulated. From there, murine xenograft models can determine in vivo efficacy of lead 
pharmacophores and zebrafish for toxicological assessment. Outside of small molecule 
screening, G4mid remains to be characterized under supercoiled conditions or within cells. 
Therefore, structurally, G4mid can be elucidated using plasmid and in cell footprinting to 
determine the biologically relevant G4 isoform (Sun & Hurley 2009; Guo & Bartel 2016). 
This knowledge will aid in drug discovery efforts using this molecular model and will have 
a positive impact on cancer (pancreatic, lung, or colorectal) patients whose tumors are 
influenced by mutant and upregulated kRAS. 
Similar to pancreatic cancer, neurodegeneration is a critical issue worldwide with 
limited therapy options. PD is one of the most common diagnoses each year. Treatments 
are limited in efficacy due to the unknown etiology of the disease and mechanisms of 
disease progression are not fully understood. Current therapeutic strategies rely on 
increasing dopamine levels, activating the motor cortex differently, or neuroprotection. 
The current work identified a new molecular target for PD resulting in increased promoter 
activity and anti-apoptosis in neurons. G41 is one of four G4s within the Bcl-2 core 
promoter and the only one capable of enhancing transcription making it essential for PD 
drug design and development. 
Using the co-solvent approach derived in our MYC G4-related studies, upon 40% 
MeCN and 10 mM KCl addition, hit rates dropped 18%. Two compounds were validated 
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by ECD to selectively stabilize G41 over the others. With E-5-12-21 being our lead 
compound, further mechanism of action confirmation is required using a series of 
neuroprotective studies examining environmental and inflammatory stress with serum 
starvation and H2O2 treatment, respectively. From here, other cannabinoid analogues and 
natural products can be screened for G41 stabilization. Lead pharmacophores can be 
administered to PD murine models for in vivo efficacy assessments. Also, zebrafish 
models for neurodegeneration can be utilized to validate pharmacophores in vivo. 
Zebrafish continue to be widely accepted for model organisms in various fields of 
research as there are over 3,000 human disease genes with zebrafish orthologues (Howe 
et al. 2013). Also, zebrafish are less expensive compared to rodent models and reproduce 
rapidly with high numbers of offspring. A PD zebrafish model has already been 
established using the neurotoxin MPTP (Xi et al. 2011). MPTP-induced PD in zebrafish 
results in decreased dopamine levels and different behavior patterns (Anichtchik et al. 
2004). Zebrafish have an orthologue of the mammalian Bcl-2 protein which can be 
monitored upon PD-induction (Jette et al. 2008). This molecular model will be one of the 
first ways to target PD by means of transcriptional control. 
Collectively, these works give insight on G4 formation in physiological conditions. 
Specifically, we examined the role epigenetic modifications play in regulation and how 
important dehydration and molecular crowding is in promoting structure formation. Poised 
with this knowledge, G4 drug discovery and development programs can improve the 
current screening methods used to incorporate physiological conditions. Overall, this will 
positively impact cancer and neurodegenerative disease patients alike and expand G4 
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drug discovery efforts to include other critical genes that are significant in biomedical 
research. 
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